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Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approx-
imately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their manage-
ment involves neurosurgery, biological therapies, and radiotherapy. Early diagnosis of pituitary tumors while
they are smaller may help increase cure rates. Few genetic predictors of pituitary adenoma development exist.
Recent years have seen two separate, complimentary advances in inheritedpituitary tumor research. The clinical
condition of familial isolated pituitary adenomas (FIPA) has been described, which encompasses the familial
occurrenceof isolatedpituitaryadenomasoutsideof the settingof syndromic conditions likemultipleendocrine
neoplasia type 1 and Carney complex. FIPA families comprise approximately 2% of pituitary adenomas and
represent a clinical entity with homogeneous or heterogeneous pituitary adenoma types occurring within the
same kindred. The aryl hydrocarbon receptor interacting protein (AIP) gene has been identified as causing a
pituitary adenoma predisposition of variable penetrance that accounts for 20% of FIPA families. Germline AIP
mutations have been shown to associatewith the occurrence of large pituitary adenomas that occur at a young
age, predominantly in children/adolescents and young adults. AIP mutations are usually associated with so-
matotropinomas, but prolactinomas, nonfunctioning pituitary adenomas, Cushing disease, and other infre-
quent clinical adenoma types can also occur. Gigantism is a particular feature of AIP mutations and occurs in
more than one third of affected somatotropinoma patients. Study of pituitary adenoma patients with AIP
mutationshasdemonstrated that these cases raise clinical challenges to successful treatment. Extensive research
on the biology of AIP and new advances in mouse Aip knockout models demonstrate multiple pathways by
which AIP may contribute to tumorigenesis. This review assesses the current clinical and therapeutic charac-
teristics of more than 200 FIPA families and addresses research findings among AIPmutation-bearing patients
in different populations with pituitary adenomas. (Endocrine Reviews 34: 0000–0000, 2013)
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Pituitary adenomas are one of the most frequent intra-cranial tumors, particularly in young patients.
Clinically relevant pituitary adenomas were shown to
occur in 1:1064 of the population in Liège, Belgium,
which has been confirmed in similar cross-sectional
studies in the United Kingdom and Switzerland, giving
an overall prevalence of 78–94 cases per 100,000 pop-
ulation (1–3). Their classically benign histology belies
their medical impact. Due to their position close to vital
local structures and the potent biological effects of pi-
tuitary hormone hypersecretion or deficiency, pituitary
adenomas can cause some of the most severe classical
conditions in endocrine practice, including acromegaly
and Cushing disease. Diagnosis and management of pi-
tuitary adenomas often involves a multidisciplinary ap-
proach that combines endocrine, neurosurgical, and ra-
diological specialists. Pituitary adenomas can also
present late with already locally expansive and invasive
disease. Although multiple effective modalities are
available, the challenges of aggressive disease behavior
remain and provide an impetus for research.
The study of pituitary adenoma pathophysiology can
takeanumberofdirections. Somegroupshavehighlighted
the molecular and signaling abnormalities within human
and animal pituitary adenomas at a somatic level. These
somatic molecular genetic abnormalities are numerous
due to the complexity of the pituitary gland itself (4–6).
Some of these discoveries have led to the experimental use
of novel therapies, such as tyrosinekinase inhibitors in this
setting (7–10). Another direction of research is into the
realmof inherited endocrine neoplasia syndromes, such as
multiple endocrine neoplasia type 1 (MEN1) and Carney
complex (CNC) (11–13). These challenging, protean clin-
ical syndromes are caused by germline genetic mutations
that impact many tissues and cause multiple endocrine
tumors, including pituitary adenomas as a characteristic
feature (14, 15). Study of these disrupted genes and the
impact of absent or abnormal protein on cellular signaling
and regulation canalsoprovide informationaboutnormal
pituitary physiology and the pathophysiology of pituitary
adenomasoccurringoutside these specific genetic settings.
These diseases provide an important clinical opportunity,
namely, to allow the early diagnosis of at-risk carriers by
germline genetic sequencing.
While MEN1 and CNC have been widely studied, nu-
merous patients and families with apparently inherited
endocrine neoplasia have been identified that have no ge-
netic abnormalities in causative genes such asMEN1 and
PRKAR1A. Interest in these cases has led to the identifi-
cation of new conditions, such as MEN4, that are only
beginning to be studied. In particular, familial isolated
pituitary adenoma (FIPA), consistingof kindredswith two
ormore relatedmembers havingpituitary adenomas in the
absence of known genetic causes, was identified and char-
acterized over the last decade, and research interest in
FIPA has led to hundreds of new kindreds being identified
worldwide. In parallel, a new gene, aryl hydrocarbon re-
ceptor interacting protein (AIP), was found to cause an
inheritable propensity for pituitary adenomas,whichhave
since been proven to represent an important cause of pi-
tuitary adenomas in young patients. Together, these two
complimentary clinical and genetic projects have high-
lighted novel findings that illustrate a group of more ag-
gressive pituitary adenomas and a molecular pathway
through AIP that opens a new understanding of pituitary
adenoma pathophysiology.
II. Familial Isolated Pituitary
Adenomas (FIPA)
A. Historical background
The medical literature on pituitary adenomas before
the naming of acromegaly by Pierre Marie was relatively
sparse (16). The promulgation of Marie’s report and de
Souza Leite’s subsequent follow-up series led to a well-
spring of clinical cases of acromegaly in the literature (17).
Focus on the signs and symptoms of acromegaly, allied
with interest in the surgical and pathological findings,
quickly led to the accumulation of a large body of funda-
mental literature on pituitary adenomas in general, in-
cluding work from leading lights such as Harvey Cushing
(18). Within these historical works are found the first sci-
entific descriptions of pituitary tumors in a familial set-
ting. The genetic etiology of these early reports is uncer-
tain, with some, like the report by Erdheim in 1903 of
pituitary and parathyroid adenomas, being strongly sug-
gestive of MEN1 (19). Indeed, the clinical reports of syn-
dromic pituitary adenomas (i.e., those occurring in asso-
ciationwith other clinical abnormalities) ledWermer (20)
to characterize MEN1 clinically (as Wermer syndrome),
and he suggested correctly the inheritance mode. Like
Wermer,Carney alsoundertookameticulous clinicopath-
ological characterization of his eponymous syndrome.
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CNCwas defined as a syndrome of myxomas, spotty pig-
mentation, and endocrine dysregulation,with acromegaly
seen in about 10% of the original case series (21, 22).
Although syndromic pituitary adenomas in the histor-
ical literature can likely be ascribed to MEN1 or other
diseases, some reports noted the occurrence of isolated
pituitary adenomas occurring in a familial setting. Rare
cases of familial gigantism from the press and advertising
materials of the 17th to 19th centuries have been well
documented by de Herder (23, 24). An early but contro-
versial scientific description that was later attributed to
familial acromegaly is Friedreich’s report (25) of the Hag-
ner brothers. Ostensibly, this report was one of bone and
joint deformities, and a plate illustrating one of the broth-
ers does not appear classically affected by acromegaly. A
monograph on acromegaly by the Austrian physician
Sternberg (26) (aided by Atkinson’s 1899 translation)
served as a detailed examination of the etiological and
clinical aspects of the disease.Here, initial cases of familial
acromegaly were discussed, such as cases reported by
Schwoner (27). Fraenkel et al. (28) later described the case
of a 50-yr-old male (“Herr Gleiche”) who presented in
1898 and had first-degree relatives with acromegalic fea-
tures (father and two siblings), and they also discussed a
three-member familial acromegaly kindred. The two
Hugo brothers were a very well-recognized familial pitu-
itary tumor kindred with acrogigantism whose media
fame crossedover into the scientific realm.While traveling
to New York, one of the brothers died of a fulminant
infection. On autopsy, the familial pituitary etiology was
strongly supported by the finding of a pituitary macroad-
enoma larger than 40 mm in diameter (29).
In 1925, Bailey and Davidoff (30) reported the clinical
features and tumorpathologyof a series of patients treated
by Cushing at the Peter Bent BrighamHospital in Boston,
Massachusetts. Case III was a 25-yr-old man who had
onset of acromegalic features as an adolescent and, as the
authors note, “came of a family of tall people. . .. His
paternal great uncle was 7 feet 1 1/2 inches tall (217
cm) . . .. the “Kentucky giant.” One could speculate that
this was the same Kentucky giant (Jim Porter) whom
Charles Dickens encountered at Portland, Kentucky, in
1842 and described in the bookAmerican Notes for Gen-
eralCirculation.Dickens’ descriptionofMr.Porter is both
sympathetic and medically suggestive: “He had a weak-
ness in the regionof theknees, anda trustfulness inhis long
face . . .. Hewas only 25 years old, he said, and had grown
recently . . .. (he) went bobbing down the cabin, among
men of six feet high and upwards, like a lighthouse walk-
ing among lamp-posts” (31). In 1937, Gray (32) outlined
the clinical history of a middle-aged male patient with
acrogigantismwho had been a silent movie actor and per-
former and noted also a reputed history of familial gigan-
tism in his grandfather. These descriptions represent in-
dividual patients or relatively small case series. In contrast,
Atkinson (the translator of Sternberg’s monograph in
1899) revisited the subject of acromegaly in a monograph
of his own in 1932 (33). This publication is an exhaustive
review of the literature up to the end of 1930 in which
Atkinson reviewedandcodified1319casesof acromegaly,
most being derived from individual case reports. The re-
view is, even today, one of the most extensive on the pre-
sentation and clinical symptomatology of acromegaly.
Among the listings of cases, Atkinson notes eight in which
acromegaly was reported to be familial in first-degree rel-
atives (seven in parents and one in a grandparent).
Kindreds with familial acromegaly continued to accrue
over the mid-to-late 20th century. The advent of immu-
noassays permitted the definitive linking of acromegaly to
excessGHsecretion, andprobably the first case of familial
acromegaly with defined hypersecretion of GH was de-
scribed by Levin et al. (34). Thereafter, a variety of other
individual case reports of familial acromegaly and acro-
gigantism were reported in the literature (35–42). The
genetic causes of both MEN1 and CNC were discovered
in the 1990s. TheMEN1 gene was initially localized to a
specific region chromosome of 11q13 (43). The MEN1
gene was ultimately cloned by researchers at the National
Institutes of Health (NIH) in 1997 (44). Mutations in the
protein kinase A I regulatory subunit gene (PRKAR1A)
on chromosome17qwerediscovered tobe related toCNC
in 1998 and subsequently have been implicated in over
70% of cases (45, 46).
Therefore, by the end of the 1990s, the concept of fa-
milial acromegaly that was unrelated to existing condi-
tions could be both clinically and genetically delineated.
Before the identification of the MEN1 gene, familial ac-
romegaly kindreds without genetic linkage to the MEN1
locus had been described initially by Benlian et al. (47)
(three members— two living, one historical) and later by
Yamada et al. (48) (three living members). These studies
noted linkage to chromosome 11q13 and loss of heterozy-
gosity (LOH) on chromosome 11q13 in tumor samples.
Subsequent to the identification of theMEN1 gene, a se-
ries of studies demonstratedmultiple kindreds with famil-
ial acromegaly and no MEN1 mutation (49–53). Such
kindreds included families with more than three affected
members, indicating a very strong likelihoodof a common
genetic cause.Most families had only somatotropinomas,
but kindreds with prolactinomas alone or in conjunction
with somatotropinomas were reported in Japan and Bel-
gium (54–56).An early, very extensiveAustraliankindred
of five affected persons was reported by Pestell et al. (38)
in 1989. Although acromegaly predominated, one subject
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had a prolactinoma, whereas another had likely co-secre-
tion of GH and prolactin from the pituitary tumor. A sub-
sequent study of three new kindreds from Lie`ge, Belgium,
reviewed the clinical findings of these and 17 other re-
ported kindreds (45 cases) (57). An autosomal dominant
inheritance pattern with reduced, age-dependent pen-
etrance was the most parsimonious model to explain the
recurrent pattern (57). Kindreds were usually small (two
affecteds), and in 50%of cases only siblingswere affected.
An early onset of disease was noted (puberty through 30
yr of age), and tumors—usually somatotropinomas, but
also somatomammotrope and plurihormonal cases—
were frequently large and invasive. These findings aremir-
rored by those of Gadelha et al. (58), also in 1999, who
used the term “isolated familial somatotropinoma” to de-
scribe these seemingly acromegaly-only kindreds. In ad-
dition to the characteristics of large tumor size and early
age at diagnosis, they also noted a male preponderance
and frequent gigantism among their studied population.
B. The emergence and characterization of FIPA
In contrast to the clear evidence for familial occurrence
of acromegaly-gigantism, the older historic scientific lit-
erature lacks firm reports of other familial pituitary tumor
types. It was not until the 1980s that viable studies of
kindreds with other pituitary tumor types came to light.
Three kindreds with familial Cushing disease were pub-
lished; two of the cases involved second-degree relatives
(aunt/nephew, aunt/niece), and one case was of Cushing
disease in two sisters (59–61). Berezin and Karasik (61)
reported three prolactinoma-only kindreds from Israel.
From Japan, there was a description of nonfunctioning
pituitary adenoma (NFPA) occurring in a familial setting
(62). Many of these kindreds were reported before the
advent of MEN1 gene mutation screening, but in those
cases, the clinical descriptions suggest a low likelihood of
MEN1.
When taken together with data from other families
noted in the previous section (38, 54–57), it became ap-
parent that pituitary adenomas other than somatotropi-
nomas couldoccur in a familial setting.To investigate this,
a specific research program was undertaken at the Uni-
versity of Lie`ge to identify kindreds with two or more
pituitary adenomas (not limited a priori to somatotropi-
nomas) in which MEN1 or CNC did not play a role. We
defined this condition as FIPA to describe the clinical find-
ings accurately and to use terminology in concordance
with analogous conditions in hereditary endocrine neo-
plasia (e.g., familial isolated hyperparathyroidism, famil-
ialmedullary thyroid carcinoma).That study identified 27
FIPA patients with somatotropinomas, prolactinomas,
and nonsecreting pituitary adenomas among a group of
1500 patients (63). Patients within the same family could
have the samepituitary tumor type in all affectedmembers
(homogeneous FIPA), or different pituitary tumor types
could exist within the same family (heterogeneous FIPA).
To confirm that the phenotype of FIPA was seen more
generally, we performed an international case-finding
study from 2000–2004 that identified new FIPA kindreds
at 22 European and North American centers (64). Nega-
tiveMEN1 genetic screening was available in at least one
affected member of each FIPA kindred, and MEN1 was
also ruled out clinically. For CNC, the situation wasmore
focused, given the more limited repertoire of pituitary tu-
mor types associatedwith this disease (normalPRKAR1A
gene sequencing was available in at least one affected
member of each homogeneous somatotropinoma kin-
dred); all FIPA kindreds were clinically screened to ex-
clude other features suggestive of CNC.
The clinical characteristics of FIPA patients (n  138)
and how they compared statistically with those of
matched sporadic nonfamilial pituitary adenoma cases
(n 288) were first described by Daly et al. (65) in 2006.
In about 75% of that cohort, the relationship between
affectedmemberswas sibling/filial in nature (first degree).
In that group, a mean of 15.4 individuals per family were
assessed, and families with two, three, and four affected
members were seen, whereas subsequent families of as
many as seven or eight persons have since been classified
as FIPA kindreds (66, 67). However, FIPA remains pre-
dominantly a condition of two to three, usually closely
related persons per kindred, albeit kindreds are usually
relatively small due to limited familial anamnesis in many
reported families. In certain FIPA kindreds where exten-
sive familial study has been possible, second- and third-
degree relationships can be noted, particularly when pho-
tographs and other historical documents (old medical
records) of deceased individuals are available for assess-
ment. In general, FIPA is present in a minority of cases of
pituitary adenomas overall, with Daly et al. (65) finding
FIPA in approximately 2% of cases from two reference
centers in one study. Multicenter epidemiological studies
on the true prevalence of FIPA in large groups of pituitary
adenoma patients are needed.
C. Clinical characteristics of FIPA
FIPA patients are diagnosed on average 4 yr before
patientswith sporadicpituitaryadenomas (65). In families
with vertical relationships between affecteds, patients in
the later generations are diagnosed with pituitary adeno-
mas at a statistically significantly younger age as com-
paredwith their parents or grandparents (on average 20 yr
before). This earlier disease diagnosis inmultigenerational
families is particularly pronounced for homogeneous
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FIPA kindreds irrespective of the tumor phenotype (65).
This is probably due to improvements over time in the
availability of diagnostic modalities [e.g., magnetic reso-
nance imaging (MRI)] and improved awareness of pitu-
itary disease in the general medical community. Also, the
sensitizing effect of having one family member with a pi-
tuitary adenoma already on improved recognition of pi-
tuitary related symptoms in another member should not
be underestimated.
The rank order of frequency of pituitary adenoma sub-
types in individual patients from our FIPA cohort is: pro-
lactinoma (37.5%), somatotropinoma (35.0%), NFPAs
(14.5%), somatolactotropinomas (6.4%), Cushing dis-
ease (2.9%), gonadotropinomas (2.0%), plurihormonal
tumors (1.2%), and thyrotropinomas (0.5%) (65, 68, 69),
andunpublishedobservationofA. Beckers andA. F.Daly.
Therefore, as compared with the frequencies of pituitary
adenoma subtypes in the general epidemiological popu-
lation, the proportion of FIPA patients with prolactinoma
is conspicuously lower (66 vs. 37.5%), although they re-
main themost frequent overall. Theproportionof patients
with somatotropinomas is consequently much higher in
the setting of FIPA than in the general epidemiological
data (35.0 vs. 13%) (1, 65, 68, 69). Prolactinomas in FIPA
are most frequently microadenomas that occur in pre-
menopausal females; this does not differ from general
characteristics of sporadic prolactinomas. Also reflecting
the casewith sporadic prolactinomas,maleswith prolacti-
nomas in theFIPAsetting comprise aminorityof cases, but
frequently present withmacroadenomas. However, when
prolactinomas occur in the setting of heterogeneous FIPA
kindreds, they appear to have more aggressive character-
istics than sporadic adenomas, being significantly more
frequently invasive andextending toward theoptic chiasm
(65). This term “aggressive” is used in a relative sense of
tumors that aremore difficult to control therapeutically or
larger tumor size. There has only been one pituitary car-
cinoma (amalignant prolactinoma) thatwas subsequently
found to occur in a heterogeneous two-member FIPA kin-
dred (a sibling had a large nonmalignant NFPA) (70). In
our experience, somatotropinomas in FIPA are almost
equally dividedbetweenhomogeneous andheterogeneous
FIPA kindreds (65, 69, 71). Patients from FIPA kindreds
with homogeneous acromegaly correspond to the previ-
ous terminology of isolated familial somatotropinoma
and share their features, havinga larger adenomadiameter
and tumors that have an earlier age of onset (57, 58, 72,
73).NFPA inFIPAmainly occur in heterogeneous families
and have a significantly younger age at onset than their
sporadic counterparts (mean, 8 yr) (65). FIPA-associated
NFPA are significantlymore frequently invasive than spo-
radic NFPA (84.6 vs. 59.6%, respectively). NFPA in FIPA
may be true null-cell adenomas or can be silent gonado-
trope-positive, silentGHpositive, silent corticotrope (type
II), or plurihormonal tumors (65, 69, 74, 75). FIPA fam-
ilies with Cushing disease, TSH adenomas, and secreting
gonadotropinomas are too rare to compare reliably
against the characteristics of sporadic groups.
III. Pituitary Adenoma Predisposition due to
Aryl Hydrocarbon Receptor Interacting Protein
(AIP) Gene Mutations
A. Genome-wide studies and the discovery of the role
of AIP mutations
In sporadic somatotropinomas, LOH at 11q13 has
been detected in a variable proportion of pituitary tumors
(57, 76–78). As noted above, studies of familial acromeg-
aly kindreds during the 1990s pointed to the involvement
of a region of chromosome 11q13 that was separate from
theMEN1 locus (47, 48, 50, 55). These studies gave rise
to important genetic linkage work that further refined the
specific region involved to an area between microsatellite
markersD11S956andD11S527 (79, 80). By2005, Soares
et al. (81) had narrowed the region in question down to a
2.21-Mb stretch of DNA on 11q13.3, but targeted se-
quencing of potential candidate genes within that region
proved negative. Among these acromegalic patients, mac-
roadenomas were relatively common, gigantism was re-
ported, and patients were relatively young at disease onset
(57, 73, 82).
The hypothesis of a possible pituitary adenoma predis-
position (PAP) gene in Finland was developed indepen-
dentlywhen three clusters ofMEN1-negative families seg-
regating acromegaly/gigantism and prolactinomas were
detected in northern Finland. This familial occurrence of
isolatedpituitary adenomasnot limited toacromegaly and
without features of known syndromes prompted consid-
eration of a previously uncharacterized form of low-
penetrance PAP. Pedigree genealogy reaching back to the
1700s was available by combining information from the
Finnish population register and parish registers. The ge-
nealogy analysis established a link between two families,
whereas the third cluster appeared to be separate. The two
linked clusters were found to have a common ancestor
couple born in 1763 and 1770. Names in the pedigree
genealogy were then combined with data from a previ-
ously characterized, population-based cohort of 54 acro-
megaly patients, diagnosed with GH-secreting adenomas
between 1980 and 1999 in Oulu University Hospital,
northern Finland (83). This enabled the construction of a
complete pedigreewith affected status (Fig. 1).Altogether,
11 affected individuals were identified. This genealogy
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wasnot limited to acromegaly only because therewere five
members with prolactinoma, four with somatotropi-
noma, and two with mixed GH/prolactin-secreting pitu-
itary adenoma. The disease predisposition locus was
identified in these families using whole genome single-
nucleotide polymorphism genotyping. This, togetherwith
fine mapping of the most prominent candidate region on
chromosome 11q12–13 (LOD score, 7.1), provided un-
ambiguous evidence for susceptibility locus identification
(84). The locus and pathology were termed “pituitary ad-
enoma predisposition” (PAP) (OMIM no. 102200). The
linked, more than 7-Mb long, founder haplotype segre-
gated perfectly with the acromegaly phenotype in both
pedigrees. Because the disease-associated haplotype was
extremely gene rich, containing 295 genes, a novel ap-
proach was needed to select candidate genes. For this pur-
pose, gene expression profiles were generated from pe-
ripheral blood samples of patients/obligatory carriers and
healthy controls. In the gene expression experiment, we
sought genes that were underexpressed, based on the ear-
lier literature supporting the inactivation of a tumor sup-
pressor gene in this chromosomal area locus (50, 51, 53).
In the linked region, 172 probe sets fulfilled the criteria,
and of these, 27 reached a P value0.05. Two probe sets
representing theAIP gene occupied the first twopositions,
with P values of 0.00026 and 0.00114. Therefore, AIP
was chosen as the primary candidate gene.Direct genomic
DNA sequencing in both families revealed an early stop
codon mutation, c.40CT/p.Q14X, in the first exon of
AIP. The mutation was not detected in 209 population-
matched healthy controls. The change segregated per-
fectly in patients with somatotropinoma and somatolac-
totrope type of adenoma and was also present in three
prolactinoma patients. Interestingly, two other prolacti-
noma patients with microadenomas did not share the
founder haplotype harboring the AIPmutation, thus rep-
resenting phenocopies. The existence of such phenocopies
is unsurprising given that prolactin-secretingmicroadeno-
mas are the most frequently seen pituitary adenoma in the
general population (1). Mutation screening of a northern
Finland population-based group of 45 apparently spo-
radic acromegaly patients revealed the Finnish founder
mutation p.Q14X in six patients and a splice-acceptor site
(IVS3-1GA)mutation in one patient. Overall, these two
mutations accounted for 16% of all patients diagnosed
with GH-secreting adenomas and for 40% of patients
younger than 35 yr of age at diagnosis, indicating that the
young age at onset is a useful indicator for the PAP caused
by AIP mutations. The identification of AIP as a novel
PAP gene was further confirmed when a late stop codon
mutation in exon 6 (c.910CT/p.R304X) was identified
in Italian siblings affected with somatotropinoma at the
Figure 1.
Figure 1. Pedigree of original Finnish family with pituitary adenoma due to a Q14X founder mutation in AIP. Generations are indicated with Roman
numerals. Generation I is from the 18th century. Numbers within diamonds indicate number of children. Circles, Females; squares, males; diagonal
line, deceased. Pedigree has been modified for confidentiality.
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age of 18 yr (previously reported in Ref. 53). In all avail-
able tumor samples from the mutation carriers in Finland
and Italy (including somatotropinomas, mixed GH/pro-
lactin-secreting tumors, andprolactinomas), thewild-type
allele was lost. This biallelic inactivation of AIP in the
tumors strengthened the assumption that AIP is likely to
act as a tumor suppressor (84).
B. AIP mutations in specific populations
Studies have examined theprevalenceofAIPmutations
in FIPA kindreds, in unselected populations of sporadic
pituitary adenomas, and in focused populations of pitu-
itary adenoma patients, such as young patients, and in
other nonpituitary tumors. Together, these studies have
confirmed and extended the initial findings and helped to
delineate the characteristics and epidemiology of pituitary
adenomasassociatedwithAIPmutations. For clarity, spo-
radic populations mentioned below refer to populations
that had no known family history of pituitary adenomas.
After genetic testing, pituitary adenoma patients withAIP
mutations and no known family history of pituitary tu-
mors (irrespective of whether they have unaffected muta-
tion carriers as family members) are referred to as “sim-
plex” cases by some authors (85)
1. AIP mutations in FIPA
After the report of Vierimaa et al. (84) describing AIP
as a gene associated with a predisposition to pituitary ad-
enomas in a familial setting, the role of AIP mutations in
thepathogenesis of FIPAwas investigated.Daly et al. stud-
ied an international cohort of 73 FIPA families (n  156
patients) from Europe and the Americas (71). Ten differ-
ent germline AIP mutations were noted in that study; all
but one were novel (the p.R304X mutation was noted in
another Italian family). One of the changes, R16H, al-
though highly conserved, has since been reclassified as
probably being a variant of no pathogenic effect that does
not map with the FIPA phenotype in some families (86–
88). This study illustrated some of the characteristics of
AIPmutation-positive FIPA patients.AIPmutations with
pathogenic effects explained only aminority of FIPA fam-
ilies (20%). A missense mutation, p.R271W, involving
an important, conserved residue was found to cause dif-
ferent tumor patterns in two unrelated families, with ac-
romegaly/gigantism in one kindred (described initially in
Ref. 47) and somatotropinoma/prolactinoma in the sec-
ond; this indicated that the same mutation in AIP could
give rise to varying pituitary adenoma phenotypes in dif-
ferent kindreds. The p.K241E missense mutation, also in
an important conserved residue, was associated with a
two-sibling FIPA family (gonadotrope and -subunit-
positive NFPA patient and a prolactinoma patient), dem-
onstrating thatAIPmutations are not invariably related to
somatotropinoma and prolactinoma-expressing kindreds
only, and also included NFPA. In terms of demographic
characteristics, themeanage at diagnosiswas significantly
lower in FIPA subjects with AIP mutations than those
FIPA patients without mutations, and the mean maximal
diameter of pituitary adenomas in theAIPmutation-bear-
ing patients was significantly larger as compared with
those withoutAIPmutations. Family screening also iden-
tified asymptomatic AIP mutation carriers. Because the
PAP associated with AIP mutations is a condition with
incomplete penetrance, asymptomatic mutation carriers
are relatively common (67, 71, 84, 86, 89, 90).
The role of AIP mutations in FIPA families has also
been studied by other groups, both as individual kindreds
(89, 91–94) and as collaborative studies of multiple kin-
dreds (67, 86, 90, 95–97). Two studies led by the Korbo-
nits group in London have accrued and assessed the char-
acteristics of 64 FIPA kindreds (160 patients) worldwide
and studied the role of AIP mutations in the population
(67, 86). These FIPA studies are of particular interest also
because they identified AIP mutations as the cause of
many previously identified familial acromegaly families
reported by Frohman’s and Gadelha’s research groups,
Pestell et al., and others (38, 39, 51, 79, 81). In their series,
the mean age at diagnosis in the AIP mutation-positive
FIPA cases was also significantly lower than in the AIP
mutation-negative FIPA cases (approximately 16 yr). The
Korbonits group found that families with AIP mutations
had a significantly higher number of affected (3.2  1.8
cases) than AIP mutation-negative FIPA families (2.2 
0.4 cases) (86).
A combined analysis of the published results on FIPA
cohorts, including 45 novel, genetically characterized,
previouslyunreportedFIPAkindreds, shows that a total of
211 FIPA families have been described in a manner that
permits data analysis. These subdivide into 127 homoge-
neous families (60.2%) and 84 heterogeneous families. As
shown in Fig. 2A, among homogeneous FIPA kindreds,
somatotropinoma families (including those with somato-
lactotrope tumors) and prolactinoma families make up
90% of the total, with homogeneous NFPA (7.2%) being
the only other frequent familial type. The heterogeneous
FIPA cohort (Fig. 2B) contains 11 different combinations
of pituitary adenomas, although subtypes such as soma-
totropinoma-prolactinoma and combinations of soma-
totropinomas and/or prolactinomas with NFPA account
for nearly 90% of cases. However, FIPA families with
heterogeneous presentation of Cushing disease, thyro-
tropinomas, and gonadotropinomas also have been iden-
tified. Among the 211 FIPA families reported comprehen-
sively in the literature or studied by the authors, 43 AIP
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mutation-bearing FIPA kindreds have been identified.
Thus,AIPmutations appear to explain only a minority of
FIPA kindreds (20.4%): 29 homogeneous families (28 so-
matotropinoma, one NFPA), and 14 heterogeneous
families (10 somatotropinoma-prolactinoma, one soma-
totropinoma-NPFA, two prolactinoma-NFPA, and one
prolactinoma-Cushingdisease family). Therewas ahigher
proportion of AIP mutation positivity among homoge-
neous FIPA families (22.8%) as compared with heteroge-
neous FIPA kindreds (16.7%), which is largely due to
AIP-positive homogeneous acromegaly kindreds. The
proportion of homogeneous acromegaly kindreds ex-
plained by AIP mutations was 36.1%. It is important to
note that to date no homogeneous prolactinoma (n 40),
Cushing disease (n2) or gonadotropinoma (n1) FIPA
kindreds have been shown to be AIPmutation positive in
our analysis or in those from the other large international
collaborative group (67, 86, 98).
2. AIP mutations in unselected sporadic
populations
A germline AIP mutation was initially
identified in16%of seemingly sporadic ac-
romegaly patients without a known family
history of pituitary adenoma from the
same geographical region of Finland (84).
Studies of unselected sporadic pituitary ad-
enoma patients have shown a low rate of
AIP mutations. A general population-
based study of 460 pituitary adenoma pa-
tients representing genetically heteroge-
neous populations fromEurope andNorth
America had an overall prevalence of AIP
mutations of less than 2% (99). Using se-
quencing and multiplex ligation-depen-
dent probe amplification (MLPA) for AIP
mutations in 148 patients (germline and
somaticDNA), Barlier et al. (100) noted an
even lower prevalence (0.7%). More re-
cently, Cazabat et al. (101) performed a
large, single-center screening approach in
443 patients with sporadic pituitary ade-
nomas. This study noted that AIP muta-
tions account for no more than 3.6% of
unselected pituitary adenomas overall
(4.5% of prolactinoma patients, 4.1% of
acromegalicpatients, 6.8%ofCushingdis-
ease patients, and1%ofNFPApatients).
Taking these and other studies in general
sporadic pituitary adenoma populations
together, AIP mutations occur at a rela-
tively low frequency of less than 4%,
meaning that unselected screening efforts
are probably not a highly efficient method
for identifyingAIPmutation-positive cases in the general,
nonfamilial pituitary tumor patient population (67, 91,
92, 95, 100–104).
3. AIP mutations in young adult patients
In the original study on AIP mutations and pituitary
tumors, the Finnish founder mutation p.Q14X and the
splice site mutation IVS3–1GA accounted for a signifi-
cant fraction of population-based acromegaly patients,
especially theonesdiagnosedat an early age (sixof15aged
35 yr at diagnosis) (84). Since then it has been estab-
lished that young age at onset/diagnosis is a characteristic
feature of AIP-related pituitary adenomas. Among large
heterogeneous international populations of pituitary ad-
enoma patients, AIP mutations tend to occur rarely (0–
3.6%) when unselected populations are studied (67, 92,




Figure 2. Proportions of 211 FIPA kindreds with homogeneous (A) or heterogeneous (B)
presentation of pituitary adenomas within the same family. GH, Somatotropinoma
(includes also somatolactotrope tumors); PRL, prolactinoma; ACTH, Cushing disease;
LH/FSH, gonadotropinomas; TSH, thyrotropinomas.
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identified are almost invariably found in younger patients.
For example, Georgitsi et al. (99) reported that AIP-re-
lated pituitary adenomas occurred in 5.5 and 7.4% of
those aged less than 45 and less than 40 yr of age at di-
agnosis, respectively. Although in unselected cases the
prevalence of AIPmutations fell to 0–1.8%, all but three
cases had disease onset before the age of 30, and one pa-
tient was an 8 yr old child. Similarly, Barlier et al. (100)
found that only one of 148 (0.7%) unselected cases from
Marseille/Lie`ge bore an AIP mutation: a somatotropi-
noma in a male aged 24 yr at diagnosis. In the large Pa-
risian cohort of unselected pituitary adenoma patients
noted above,AIPmutations were detected in 3.6% (16 of
443) of cases, of which seven were diagnosed before the
age of 18 yr (107). Occhi et al. (95) reported a similar
overall rate of deleterious AIP changes in Italian patients
(3.1%), although the age at diagnosis was higher with all
four patients age 30 yr or older at diagnosis. Studies in
FIPA kindreds from various groups have shown that AIP
mutation-bearing patients are generally young at diagno-
sis (67, 71, 86) and significantly younger than FIPA cases
withoutAIPmutations (67, 71, 86). We performed a spe-
cific screening study that was limited to sporadic patients
with two of the most characteristic features of AIP mu-
tation-related pituitary adenomas: young age (30 yr of
age) andmacroadenomaat diagnosis (108).GermlineAIP
mutations were found to occur in 19 of 163 patients
(11.7%), rising to 20.5% of pediatric/adolescent patients
(aged18 yr at diagnosis). Overall, 13% of somatotropi-
nomas, 11.5% of prolactinomas, and one of 16 (6.3%)
NFPA had germline AIP mutations. Although these pa-
tients had no known history of FIPA, six of seven families
of affected patients that permitted testing revealed AIP
mutation carriers (two asymptomatic microadenomas
were diagnosed in carriers).
4. AIP mutations in pediatric and adolescent patients
Theoccurrenceof pituitary tumors among children and
adolescent patients is rare, andapproximately2–6%ofall
surgically treated pituitary adenomas occur in young
patients—prolactin- and ACTH-secreting adenomas be-
ing the most common types. Pediatric somatotropinomas
are usuallymore aggressive than those in adults (106, 109,
110). Studies have examined AIP mutation prevalence
among populations that specifically included children and
adolescents (i.e., those aged18 yr at diagnosis or disease
onset).A screening studywasperformedbyGeorgitsi et al.
(104) in a specific, sporadic, non-FIPA pediatric popula-
tion (n36) aged less than18yr at diagnosis or at the time
of first signs/symptoms of a pituitary adenoma. Two pa-
tientswere found tohave pathologicalAIPmutations; one
was a male with gigantism due to a large somatotropi-
noma, and the other had aNFPAat the age of 15 yr, giving
an overall prevalence in this pediatric series of 5.6%. Sub-
sequently, Stratakis et al. (109) reporteda seriesofpatients
from the NIH Clinical Center in the United States. This
was a diverse population of patients with and without
familial or associated syndromic disease features. One of
74 pediatric patients (1.4%) with isolated sporadic Cush-
ing disease had an AIP mutation; this patient was diag-
nosed at age 6 yrwith amicroadenoma that recurred post-
surgically and required radiotherapy to achieve control,
resulting in panhypopituitarism. Two pediatric patients
with non-FIPA sporadic somatotropinomas (n  1) or
prolactinomas (n1) hadAIPmutations; bothweremac-
roadenomas, and one was a de novomutation, which re-
mains the only case reported to date. Finally, one 11-yr-
old patient from a heterogeneous FIPA family with a
somatolactotrope macroadenoma had an AIP mutation,
which was poorly responsive to somatostatin analogs and
required three operations and radiotherapy. Interestingly,
that patient’s tumor had zones of hyperplasia on patho-
logical analysis, a novel feature that was later reported in
fraternal twin sisters with silent somatotrope adenomas
anda separateAIPmutation (75). In the latter study, itwas
noted that while the adenoma tissue had LOH forAIP, as
would be expected by the Knudson two-hit hypothesis,
both the hyperplastic and normal pituitary tissues did not
have LOH for AIP. This suggests that if the hyperplastic
and adenomatous tissue were pathologically part of the
same process, then loss of the wild-type allele may be a
relatively late event in tumorigenesis inAIP-mutated FIPA
kindreds. Overall in the NIH series, eight of 88 (9.1%)
patients had mutations in either AIP or MEN1 genes, of
which AIP comprised four of 88 cases (4.5%), although
this population was predominantly Cushing disease pa-
tients, in which the rate ofAIPmutations is low. A higher
rate of AIP mutations appears to be present in pediatric
and adolescent populations with macroadenomas, be-
cause Tichomirowa et al. (108) reported 20.5% of pa-
tients aged less than 18 yr at diagnosis had a germlineAIP
mutation. Similar evidence has been noted in a French
series of 443 sporadic pituitary adenoma cases (101); of
these cases, 30 were aged less than 18 yr at diagnosis, and
23.3% were noted to have germline AIP mutations. Pe-
diatric/adolescent cases ofAIPmutation-related pituitary
adenomas, like their adult counterparts, are generally so-
matotropinomas, prolactinomas, mixed GH/prolactin-
secreting adenomas, although Cushing disease cases are
also seen.
C. Founder AIP mutations
The p.Q14X mutation has been described in the Finn-
ish population and from haplotype and genealogical data
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is considered a founder mutation. A patient from Estonia
with the samemutation has been noted and is possibly due
to migration of this patient’s ancestors from Finland
(111). Founder mutations for a number of diseases (often
recessive) have been described in Finland due to specific
patterns of geographically delimited genetic drift in orig-
inal founding populations after the last Ice Age, to which
gene flow from Scandinavian populations to the west and
southhas created somestrikingdifferencesbetween south-
ern/western and northern/eastern Finland. We cannot
speculateonwhen the foundingAIPmutationoccurred, in
fact, although Finnish genealogical and parish informa-
tion provide an excellent database. Historical evidence
does point to many relevant cases coming from the same
regionof Finland.DanielCajanus, a northernFinnishman
from Paltamo (modern province of Kainuu) was affected
by gigantism in the early 18th century, and his sister and
cousin also reputedly suffered from tall stature and en-
larged extremities, respectively. Another man with gigan-
tism from Tornio, northern Finland, was also noted some
70 yr previously (112), whereas other well-known pa-
tients with acrogigantism either came from or had family
from Paltamo (Va¨ino¨Myllyrinne) or the nearby Puolanka
[Lauri (Louis) Moilanen]. All of these cases came from or
had their origin in a limitedgeographical area separatedby
no more than 200 km and also very close to Oulu, where
many of the p.Q14X cases are currently cared for.
The p.R304X mutation has also been shown to be a
founder mutation. The first published evidence of this
came from Occhi et al. (96) who compared the microsat-
ellite marker pattern around the loci for the AIP and
MEN1 genes in three Italian families, two of which were
previously described (71, 84). Haplotyping showed that
two of the families shared alleles that suggest a common
ancestor, probably in the Lazio region from which they
originated. Subsequently, Chahal et al. (90) connected a
historic case of acrogigantism to four FIPA families from
Northern Ireland, via a common p.R304X mutation of
AIPwith a common ancestor between approximately 375
and 3750 yr ago. Among patients with gigantism, the case
of Charles Byrne has probably been the best documented
in the popular and scientific literature (113, 114). He was
born in County Derry in the Irish Province of Ulster, and
following his death in 1783, his skeleton has been on pub-
lic display, currently at theHunterianMuseum inLondon.
Extracting DNA from the teeth, Chahal et al. (90) dem-
onstrated that Charles Byrne’s gigantism (and enlarged
pituitary fossa as shown byCushing a century before) was
also due to a p.R304X AIP mutation and had a shared
haplotype with the four modern-day FIPA families. The
p.R304 residue of AIP is a hot spot for truncating muta-
tions (c.910 CT) and also for a missense p.R304Q mu-
tation (c.911 GA), due to its being a CpG site; multiple
FIPA families and simplex caseswith thesemutations have
been described across the globe (Table 1). Similarly, other
pathological mutations, such as p.R271W, p.K241E/
p.K241X, and p.R81X also have been shown to act as hot
spots in multiple kindreds (71, 109, 115–117).
D. AIP mutation screening: current status
Based on a review of the published literature, online
resources such as GenBank and the authors’ own unpub-
lished screening results, a total of 215 patients with AIP
mutations and pituitary adenomas have been reported. As
shown inTable 1, to date, 70differentAIPmutations have
been identified. Mutations in AIP occur relatively evenly
throughout the coding region of the gene. All of these
mutations have been germline mutations, and no somatic
AIP mutations have been found in pituitary tumors. Dif-
ferent mutation types include nonsense, missense, splice
site, insertion, deletion, frameshift, and promoter region
mutations, as well as heterozygous deletion of most of or
the entire AIP gene. Nonsense mutations and frameshifts
leading to truncations account for half of reported AIP
mutations. The missense mutations shown in Table 1 in-
volve residues that are highly conserved and/or have been
shown to correlate with altered in vitro activity in the
published literature. Similarly, a variety of groups have
used various in silico and in vitro methods to verify the
pathogenicity of many intronic/splicing mutations. How-
ever, in cases where clear deleterious effects or correlates
of genetic variants are not clearly present, caution should
be used before labeling them as mutations, and a more
conservative terminology such as “a variant of unknown
significance” may be employed.
The most common mutations of the AIP gene are
p.R304X (n  35 patients), p.Q14X (n  19 patients),
p.R271W (n  10 patients), and p.R304Q (n  10 pa-
tients). As screening procedures have expanded globally,
other mutations such as p.R81X appear to be growing in
frequency. As seen in Fig. 3A and Table 1, the pituitary
adenomas definitively diagnosed in association with AIP
mutations consist of 132 somatotropinomas, 19 soma-
tolactotropinomas, 29 prolactinomas, 13 NFPAs, four
Cushing disease, one thyrotropinoma, one gonadotropi-
noma, and one plurihormonal tumor (tumor type not
available; n  15). The population remains predomi-
nantly male (61.2%), and the majority of patients present
with macroadenomas (88.3%). Most cases present as
FIPA (68.2%). Other cases may be pure simplex cases in
which only one known AIP mutation-positive pituitary
adenoma patient exists among a family of AIP mutation
carriers (7.6%). So-called sporadic cases (24.2%) are
likely to be a mix of classifications. Many will be cases in
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c.64CT R22X 2 Familial (2
separate)
Somatotropinoma (2) M (2) 11, 22 Macroadenoma (2) 1 France (1), Spain
(1)
c.70GT E24X 7 FIPA (7) Somatotropinoma (3),
somatolactotropinoma
(1), N/A (3)






c.241CT R81X 4 FIPA (4) Somatotropinoma (4) M (2), F (2) 14, 25, 34, 36 Macroadenoma (4) 1 United States
(2), Brazil (2)
c.424CT Q142X 3 FIPA (3) Somatotropinoma (3) M (2), F (1) 17 (2), 29 Macroadenoma (3) 1 Italy (3)
c.490CT Q164X 2 FIPA (2) Somatotropinoma (2) M (1), F (1) 20, 23 Macroadenoma (2) 2 Germany (2)
c.550CT Q184X 1 Familial Somatotropinoma (1) M (1) 21 Macroadenoma (1) 1 Italy
c.601AT K201X 2 Sporadic (2) Somatotropinoma (2) M (1), F (1) 24, 27 Macroadenoma (2) France (2)
c.646GT E216X 2 FIPA (2) NFPA (silent
somatotrope; 2)
F (2) 12, 17 Macroadenoma (2) France (2)
c.649CT Q217X 2 FIPA (2) Somatotropinoma (1),
somatolactotropinoma
(1)
M (1), F (1) 23, 28 Macroadenoma (1),
microadenoma (1)
Belgium
c.662dupC E222X 2 FIPA (2) Somatotropinoma (2) M (2) 24, 28 Macroadenoma (2) United Kingdom
c.715CT Q239X 2 FIPA (2) Somatotropinoma (2) M (2) 14, 15 Macroadenoma (2) 2 France (2)
c.721AT K241X 1 Sporadic (de novo) Prolactinoma M (1) 18 Macroadenoma (1) United States (1)
c.783CG Y261X 2 Sporadic (2) Somatotropinoma (1),
somatolactotropinoma
(1)
M (2) 17, 28 Macroadenoma (2) 2 France (2)
c.804AC Y268X 3 FIPA (2), familial (1) Somatotropinoma (2),
prolactinoma (1)
M (1), F (2) 23, 24, 29 Macroadenoma (3) Brazil (3)
Q285X 1 Familial Somatotropinoma (1) M (1) 60 Macroadenoma (1) The Netherlands






































c.3_4insC R2fsX43 4 FIPA (4) Somatotropinoma (2),
NFPA (silent
somatotrope; 2)







c.88_89del GA D30TfsX14 1 Sporadic (1) NFPA M (1) 19 Macroadenoma France
c.74_81delins7 L25PfsX130 5 FIPA (5) Somatotropinoma (3),
somatolactotropinoma
(1), prolactinoma (1)





c.244_248delGAAGG E82fsX7 1 Sporadic (1) Somatotropinoma (1) M (1) 15 Macroadenoma (1) Bulgaria
c.249GT G83AfsX15 3 FIPA (3) Somatotropinoma (1),
prolactinoma (2)
M (3) 14, 60, N/A Macroadenoma (2),
N/A (1)
1 United Kingdom
c.286_287delGT V96PfsX32 3 FIPA (3) Somatotropinoma (3) M (3) 22, 26, 52 Macroadenoma (2),
empty sella (1)
2 Japan
c.350delG E117AfsX39 3 Sporadic (3) Somatotropinoma (1),
prolactinoma (2)
M (2), F (1) 16, 18, 30 Macroadenoma (3) France
c.338insACCC P114fsX 1 Sporadic (1) Somatotropinoma (1) F (1) 12 Macroadenoma (1) 1 United States
c.404delA H135LfsX21 1 Sporadic (1) Somatotropinoma (1) M (1) 14 Macroadenoma (1) 1 France
c.500delC P167HfsX3 6 FIPA (6) N/A (6) M (2), F (4) N/A N/A (6) Malaysia
c.517_521delGAAGA E174fsX47 3 FIPA (3) Somatotropinoma (2),
somatolactotropinoma
(1)
M (1), F (2) 17, 25, 35 Macroadenoma (2),
microadenoma (1)
1 Brazil
c.543delT L181fsX13 6 FIPA (6) Somatotropinoma (2),
prolactinoma (1),
NFPA (1), N/A (2)








c.752delT L251RfsX52 1 Sporadic (1) Cushing disease (1) F (1) 25 Macroadenoma (1) France
c.824_825insA H275QfsX12 1 Sporadic (1) Somatotropinoma (1) M (1) 8 N/A (1) United States
(Continued)

















c.854_857delAGGC Q285fsX16 2 FIPA (2) Somatotropinoma (2) M (2) 20, 33 Macroadenoma (2) 1 Italy
c.919insC Q307fsX104 2 FIPA (2) Somatotropinoma (1),
prolactinoma (1)
M (1), F (1) 11, N/A (1) Macroadenoma (2) United States
Inframe duplication


















2 FIPA (2) Somatotropinoma (2) F (2) 10, 14 Macroadenoma (2) 2 Japan
Inframe deletions
c.66_71delAGGAGA delG23_E24 1 Sporadic (1) Somatotropinoma (1) M (1) 20 N/A (1) Germany
c.138_161del24 delG47_R54 2 FIPA (2) Somatotropinoma (2) M (2) 25, 28 Macroadenoma (2) Argentina








2 FIPA (2) Somatotropinoma (2) M (1),
N/A (1)


























3 FIPA (3) Somatotropinoma (3) M (3) 19, 23, 35 Macroadenoma (3) United Kingdom
Full gene deletion Exon 1–6
deletion
2 FIPA (2) Somatotropinoma (2) M (1), F (1) 10, 20 Macroadenoma (2) 2 Serbia
Missense mutations
c.26GA R9Q 2 Sporadic (2) Cushing disease (1),
prolactinoma (1)




c.166CA R56C 1 Sporadic (1) Prolactinoma M (1) 26 Macroadenoma (1) Bulgaria
c.174GC K58N 2 Sporadic (2) Prolactinoma (1),
gonadotropinoma (1)
M (1), F (1) 20, 32 Macroadenoma (2) France
L70M 2 FIPA (2) Somatolactotropinoma
(1), prolactinoma (1)
M (1), F (1) 22, 60 Macroadenoma (2) Italy
c.250GA E84K 1 Sporadic (1) Somatolactotropinoma F (1) 22 Macroadenoma (1) Ukraine
c.308AG K103R 1 Sporadic (1) Cushing disease M (1) 6 Microadenoma (1) United States
c.509TC M170T 1 Sporadic (1) Somatotropinoma M (1) 32 Macroadenoma (1) 1 France
c.563GA R188Q 1 Sporadic (1) Prolactinoma F (1) 24 Microadenoma (1) France
c.584TC V195A 1 Familial Prolactinoma M (1) 12 Macroadenoma (1) Brazil
c.713GA C238Y 3 FIPA (3) Somatotropinoma (3) M (3) 19, 21, 23 Macroadenoma (3) Mexico
c.718TC C240R 3 FIPA (3) Somatotropinoma (3) M (3) 13, 15, 25 Macroadenoma (3) 1 France
c.721AG K241E 2 FIPA (2) Prolactinoma (1), NFPA
(1)
M (1), F (1) 39, 53 Macroadenoma (2) Belgium
c.769AG I257V 1 Familial Thyrotropinoma M (1) 39 Macroadenoma (1) Spain
c.803AG Y268C 1 Familial Prolactinoma M (1) 28 Macroadenoma (1) Belgium















c.829GC A277P 1 Familial Somatolactotropinoma
(1)
M (1) 12 Macroadenoma (1) 1 Italy
c.871GA V291M 1 Sporadic (1) Somatolactotropinoma
(1)
F (1) 30 N/A (1) Italy
c.872TA V291E 1 Sporadic (1) Somatolactotropinoma
(1)
M (1) 21 Macroadenoma (1) 1 France























c.974GA R325Q 1 Sporadic (1) Prolactinoma F (1) 18 Macroadenoma (1) France
(Continued)
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which familial screening for pituitary disease and/or AIP
mutations was not offered, was declined, or is not re-
ported, andas such,many could represent either unknown
FIPA kindreds or simplex cases. Only one de novo muta-
tion in AIP has been reported in a sporadic patient (109).
Figure 3B shows the distribution of age at diagnosis
among the known cases of AIP-associated pituitary ade-
nomas. This confirms the consistent impression since the
original studies on AIP that young age at diagnosis is a
clear feature of this disease (71, 84, 99). A total of 78.0%
of patients were diagnosed at or before the age of 30, and
only a further 11.5% were diagnosed between 30 and 40
yr of age. Three patients had empty sella and a distant
history of headache and acute illness that suggested apo-
plexy.Asnotedby Igreja et al. (86) in their series, apoplexy
was a presenting feature in 8% of their 63 cases and has
been noted in acute presentation by others in the FIPA
setting (75, 86, 90, 118). Specific studies on series of pa-
tients presenting with pituitary tumor apoplexy may con-
firm this to be a suggestive feature of AIP mutation car-
riage. Gigantism occurred in more than one third of
somatotropinoma cases (36.0%) and accounts for one
fourth of all cases ofAIPmutations reported to date. This
confirms the finding from a specific comparison of AIP
mutation-related somatotropinomas vs. sporadic AIP-
intact cases that gigantism is significantly more common
in the setting of AIP mutations and represents a charac-
teristic phenotypic feature of the disease (115).
Most of theAIPmutations noted in Table 1 were iden-
tified by sequencing approach. Some patients harbor large
germline AIP deletions, which are undetectable by tradi-
tional sequencing methods (86, 105). To identify such
germline mutations, the use of the MLPA technique is
needed and has proven useful in the demonstration ofAIP
genetic abnormalities, although in a relatively limited
number of cases (86, 100, 105), and in numerous large stud-
ies no mutations were revealed by this method (95, 101,
108). MLPA studies in populations that are negative for
AIPmutations on standard sequencing are, however, use-
ful to identify those rarer instances of gene deletions (85).
E. Treatment outcomes in AIP-mutated
pituitary adenomas
The characteristics ofAIP-mutatedpituitary adenomas
as being large and expansive tumors occurring at a young
age suggest a negative impact on treatment outcomes.
Also, early evidence pointed to a possibility for AIP-mu-
tated somatotropinomas to be relatively resistant to the
effects of somatostatin analogs (67, 89). These and other
characteristics were studied specifically in a series of 96
patients with AIP mutations and pituitary adenomas to
determine whether larger tumor size translated into diffi-
culties in disease control (115). Among the group, soma-
totropinomas were the most frequent type (n  75), and
these patients were compared with a control group of 232
acromegaly patients without AIP mutations (Table 2).
The AIP mutation group had significantly more males
than control acromegaly patients. As expected from pre-
vious studies, AIP mutation-related tumors were signifi-
cantly larger and more frequently had extrasellar exten-
sion at diagnosis. Fifty-two percent of acromegaly cases in
theAIPmutation group had first symptoms before the age
of 18 as compared with less than 5% of controls. Gigan-
tism was significantly more common among the AIPmu-
tation group vs. controls, and all cases of gigantism in that
group occurred in males. The increased tumor size was
associated with higher GH secretion at diagnosis in the
AIP-mutated group vs. controls, whereas prolactin co-
secretion was present in 56 and 29% of the AIP-mutated
and control populations, respectively. These comparisons
were all statistically significant (115).
After a follow-up of at least 1 yr, acromegaly patients
with AIP mutations had a similar overall rate of disease



















c.591GA E197E 2 Sporadic (2) Somatotropinoma (2) F (2) 23, 66 Macroadenoma (2) Italy (1),
Lebanon (1)














IVS3–2AG 2 Sporadic (2) Somatolactotropinoma
(1), prolactinoma (1)
M (2) 16, 40 Macroadenoma (2) France (2)
IVS3  1GA 1 Sporadic (1) Somatotropinoma F (1) 62 Microadenoma (1) Italy
IVS3–1GA 1 Sporadic (1) Somatolactotropinoma F (1) 26 Microadenoma (1) Finland
IVS2–1GC 1 Sporadic (1) Somatotropinoma M (1) 17 Macroadenoma (1) United States
The predicted effect on protein, where known, is included. Missense mutations are included based on having demonstrable effects in vitro, in silico, or occurring in
highly conserved domains within the AIP molecule. M, Male; F, female; N/A, not available.
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with somatotropinomas in the setting of AIP mutations
required a second or third neurosurgical intervention sig-
nificantly more frequently than controls (22 vs. 6%, re-
spectively). Although radiotherapy was employed more
frequently in theAIPmutation group (41%) as compared
with controls (25%), this did not reach statistical signif-
icance. In patients with AIP mutations treated with so-
matostatin analogs, the median percentage decreases in
GH and IGF-I secretion were significantly lower than in
the acromegalic controls (Fig. 4). These differences were
unaffected when preoperative, primary, and postopera-
tive somatostatin analog use was assessed sep-
arately. In parallel, a smaller degree of tumor
shrinkage was noted with somatostatin ana-
logs in the AIPmutation group vs. control pa-
tients. FourAIPmutation-bearingpatientshad
complete resistance to somatostatin analogs
and tumor growth while on treatment.
Similar to the case with somatotropinomas,
patients with AIP mutation-related prolacti-
nomas (n  13) also displayed features that
suggested relative resistance to treatment.
More than three fourths of patientsweremales
who were at a young age at the time of first
symptoms (50%were younger than 18 yr). As
with somatotropinomas, tumors were also
large at diagnosis (only one was a microad-
enoma), and invasion of local structures had
already occurred at diagnosis in nine of 13
cases. All but one case received dopamine ag-
onist treatment, and overall efficacy was rela-
tively poor (five of 12 cases controlled ini-
tially), leading to a need for surgery in seven
patients, of whom one had four neurosurgical
interventions and three underwent two trans-
sphenoidal operations each. Importantly, rel-
atively poor responses to dopamine agonists
were seen, including cases of primary and sec-
ondary resistance. The reason for this charac-
teristic remains unclear because dopamine D2
receptor studies were not performed on the tu-
mor tissues from these patients. Information
on NFPA and other tumor types was based on
small patient numbers, and conclusions aredif-
ficult to draw from the limited data.
Overall, patientswithAIPmutation-related
pituitary adenomas usually have somatotropi-
nomas/somatolactotropinomas or prolactino-
mas; in the course of clinical management,
these tumors appear to have relatively poor
medical therapy responses and require more
frequent reoperation.Thebasis for the reduced
response to somatostatin analogs in terms of hormonal
reduction and tumor size changes is unknown. Further
study of important determinants, such as tumor expres-
sion of somatostatin receptors 2 and5 andparticularly the
truncated form of somatostatin receptor subtype 5 or
other factors thatdetermineoctreotide responses is needed
(119–125). Recent work from Chahal et al. (126) points
to a potential mechanism via the zinc finger transcrip-
tion factor ZAC1. ZAC1 is highly expressed in normal
pituitary but is down-regulated in pituitary adenomas
(123, 125); importantly, AIP expression is increased in
Figure 3.
Figure 3. A, Percentage of patients with different pituitary adenoma types seen in
patients (n  215) with germline AIP mutations. B, Distribution of AIP mutation-
positive pituitary adenoma population by age at diagnosis (divided into 5 yr cohorts).
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tumors from patients previously treated with soma-
tostatin analogs before surgery (126).
F. Role of AIP mutations in other tumor types
To date, the only tumors that have been found to un-
ambiguously associate with AIP mutations are pituitary
adenomas, which contrasts with MEN1, MEN4, and
CNC, where several other tumor types are found among
the typicalmanifestations.Mutation screening in a total of
499 colorectal, breast, and prostate cancers was per-
formed (127). These tumors, apart from being the most
prevalent among men and women worldwide, have been
associated with acromegaly, particularly colorectal neo-
plasia. In this material, no somatic AIP mutations were
identified. The occurrence of somatic AIP mutations has
been studied also in nonpituitary endocrine tumors and
familial nonmedullary thyroid cancer (128, 129). Alto-
gether, 79 sporadic tumors of endocrine system, including
thyroid, adrenal, and parathyroid lesions, carcinoids and
adenocarcinoids, paragangliomas, and pancreatic tumors
were screened with negative results; no germline AIPmu-
tations were detected in familial nonmedullary thyroid
cancers either.
Interestingly, loss of wild-type allele was recently re-
ported in an adrenocortical carcinoma of an acromegaly
patient with a germline AIP mutation (p.R81X) (130).
However, the 11q13 LOH, in the regionwhere theMEN1
gene is also located, could also be accompanied by a germ-
line defect in another, as yet unidentified, tumor suppres-
sor gene at 11q13. The existence of such a gene related to
adrenocortical tumorigenesis has been suggested previ-
ously (12, 131). Although other groups have also noted
nonpituitary tumors in patients with AIP mutations, no
consistent pattern has emerged (67), and recently an as-
sociationbetweenmeningiomaandAIPmutationwasdis-
counted in a patientwith a pituitary adenoma (117). Iden-
tification of rare tumor associations with AIP, which is
already a quite low penetrance gene, may require further
long-term follow-up of large numbers of affected individ-
uals and mutation carriers. Hibernomas are benign neo-
plasms displaying cytogenetic rearrangements involving
chromosome band 11q13. A recent study of Nord et al.
(132) suggestedMEN1 andAIP deletion to be involved in
the pathogenesis of these brown fat tumors, but these tu-
mors have, as yet, not been identified in carriers of germ-
line AIP mutations.
IV. Mouse Models and in Vitro Studies of AIP
in Pituitary Tumor Biology
Mouse models have been widely used to study pituitary
development, function, and disease to gain important
insight into the role of particular genes in different path-
ways and the nature of tumor development in the pitu-
itary gland.Moreover, if the mouse model recapitulates
the phenotype of human disease, it can offer a platform
in which to test new drugs or targeted therapies for
patients.
A. Phenotypes of Aip knockout mouse models
The firstAipmousemodel was published by Lin et al.
(133). Homozygous Aip loss was associated with em-
bryonic lethality due to the congenital cardiovascular
abnormalities such as a double-outlet right ventricle,
ventricular septal defects, and pericardial edema at an
TABLE 2. Clinical characteristics of 75 AIPmut-associated and 232 control non-AIPmut somatotropinoma




Percentage males 61.3% 46.5% 0.027
Age at diagnosis (yr) 22.0 (8.0–60.0) 43.0 (16.0–72.0) 0.000001
Age at first symptoms (yr) 17.5 (4.0–50.0) 38.0 (14.0–70.0) 0.000001
Maximum tumor diameter (mm) 22.5 (7.0–60.0) 16.0 (3.0–48.0) 0.00026
Macroadenoma 93.1 80.8 0.026
Extrasellar extension (%) 65.1 49.8 0.018
Invasion (%) 51.7 38.8 0.11
GH level at diagnosis (ng/ml) 28.5 (3.3–183.0) 17.4 (1.7–180.0) 0.00068
IGF-I level at diagnosis (%ULN) 217.0 (116.0–1090.0) 210.5 (20.0–550.0) 0.48
Prolactin co-secretion (%) 56.1 28.9 0.00023
Gigantism (%) 32.0 6.5 0.000001
Extrasellar extension represents superior or lateral extension of the tumor beyond the sella on MRI/computed tomography or at surgery. Invasion represents evidence of
the presence of pituitary tumor tissue invading or penetrating the normal border of the pituitary gland. Age at diagnosis, age at first symptoms, maximum tumor
diameter, and GH and IGF-I levels at diagnosis are presented as median (range). ULN, Upper level of normal. Adapted from A. F. Daly et al.: Clinical characteristics and
therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:E373–E383,
2010 (115), with permission. © The Endocrine Society..
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embryonic age of 10.5–14.5 d. In this same study,
heterozygous (Aip/) mice were phenotypically nor-
mal and fertile. Moreover, Lin et al. (134) created a
hypomorphic Aip mouse model, which displayed a re-
duced Aip expression. Hypomorphic Aip mice showed
a patent ductus venosus resulting in reduced liver size
(134). Interestingly, failure of ductus venosus closure
has also been detected in aryl hydrocarbon receptor
(Ahr) and Ahr nuclear translator (Arnt) mouse models
(135, 136), suggesting that AIP plays an important role
in the AHR-mediated developmental pathway.
A conditional Aip mouse model where the Aip gene
was deleted in hepatocytes showed that AIP deficiency
leads to reduction of functional cytosolic AHR in the
liver and eliminates/reduces dioxin-induced hepatotox-
icity (137). AIP seemed to be required for the expression
of AHR response genes, albeit that some of the dioxin-re-
sponse genes were not dependent upon AIP coexpression.
ThisdifferentialdependenceonAIPdemonstrates thatmam-
malian genome appears to contain more than one class of
AHR-response genes and AIP may have a significant role in
the up-regulation of a subset of these (137).
Possible tumor predisposition was not a focus of the
above-mentioned Aip mouse model studies. To model
the PAP caused by germline Aip mutations
and to clarify the tumor spectrum, Raitila et
al. (138) created a conventional Aip mouse
model. The mouse model was generated by
inserting a gene trap vector construct into an
intronic region of Aip, which produced a
truncated AIP protein. Homozygous knock-
out (Aip/) mice died during embryogene-
sis, this result being consistent with the ear-
lier study of Lin et al. (133). Heterozygous
Aip mice were highly prone to pituitary ad-
enomas. Aip/mice developed pituitary tu-
mors localized in the pars distalis, which cor-
responds to the human anterior pituitary, at the
age of 6 months. No tumors were detected at 3
months, which could be explained by the true
rarity of pituitary adenomas in this age group or
possibly by the lesions being too small to be de-
tectedwith routine immunostaining. AIP immu-
nohistochemistry, as well as LOH screening,
showed biallelic inactivation of AIP. Com-
plete penetrance of pituitary adenomas was
reached at the age of 15 months (Fig. 5), em-
phasizing the fundamental importance of
Aip for pituitary tumorigenesis. The major-
ity of mice developed somatotropinomas
(88%), although mixed GH/prolactin, pro-
lactinomas, and ACTH-positive adenomas
were also detected; some adenomas grew to a very large
size (Fig. 5, B and C) (138). Aip/ mice with soma-
totropinomas had significantly elevated IGF-1 (Igf-1)
expression levels and evidence of increased internal or-
gan weight. The incidence of pituitary lesions in
heterozygous Aip mice is extremely high as compared
with known prevalence of these tumors in mice. How-
ever, no clear excess of any other tumor types was de-
tected, although a slight excess of hyperplasia of adrenal
glands was seen.
In humans, AIP-associated tumors can appear already
in childhood or early adulthood. In theAipmouse model,
the first lesions were detected at the age of 6 months, thus
in adulthood. The other main difference between the hu-
man and mouse AIP disease phenotype was the complete
penetrance of pituitary adenomas in theAipmousemodel.
Despite genomic conservation between the species (139),
many biological functions differ, and any given response
in humansmaynot occur in precisely the sameway inmice
(140). It is possible that such differences can explain these
phenotypic discrepancies observed between human and
mouse pituitary tumor onset and penetrance. Neverthe-
less, this conventionalAipmousemodel greatly resembles
human disease, displaying a pituitary tumor phenotype
Figure 4.
Figure 4. Relative resistance to somatostatin analogs in AIP mutation-related
somatotropinomas vs. controls. Patients treated with somatostatin analogs for
acromegaly who had germline AIP mutations (n  75) had a statistically significantly
lower percentage decrease from baseline in serum GH and serum IGF-I
concentration as compared with 232 wild-type AIP control patients that were
matched for age, sex, and decade of diagnosis. [Derived from A. F. Daly et al.:
Clinical characteristics and therapeutic responses in patients with germ-line AIP
mutations and pituitary adenomas: an international collaborative study. J Clin
Endocrinol Metab 95:E373–E383, 2010 (115), with permission. © The Endocrine
Society.].
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with a predominance of somatotropinomas. This suggests
that the factors underlying AIP tumorigenesis are similar
in mice and humans. Therefore, this mouse model pro-
vides an extremely useful tool to further study the AIP-
associated pituitary tumorigenesis, and it is potentially a
valuable platform for testing new therapeutic strategies
for management of patients with treatment-resistant pi-
tuitary adenomas.
B. Molecular and pathological characteristics of
AIP/Aip-associated tumors
The inactivating nature of the germline mutations, the
loss of the normal allele in tumors, as well as recent func-
tional evidence imply that the AIP gene acts as a tumor
suppressor gene (67, 84, 138, 141). Wild-type AIP ex-
pression was shown to reduce cell proliferation in a rat
somatomammotroph pituitary adenoma (GH3) cell line,
and human fibroblast (HEK293 and TIG 3) cells and the
mutant form of AIP protein lost the ability to block cell
proliferation (67). This finding was echoed in the subse-
quent work of Helio¨vaara et al. (141), which found that
Aip small interfering RNA silencing leads to a clear in-
crease of cell proliferation rates in the GH3 cell line.
HumanAIP-associated pituitary tumors havemore ag-
gressive features as comparedwithAIPmutation-negative
tumors (115), and elevated staining for Ki-67, amarker of
cell proliferation, has been demonstrated in some human
AIP mutation-related pituitary adenomas (93, 142). To
assess the aggressiveness of Aip-related tumors, the pro-
liferation rates were evaluated in a set of mouse Aip-
deficient pituitary tumors usingKi-67 immunohistochem-
istry. The Aip-associated tumors had significantly higher




Figure 5. Aip mouse model phenotype. A, Pituitary adenoma prevalence in heterozygous (Aip/) and wild-type (Aip/) mice. B, Normal
pituitary gland of wild-type mouse. C, Macroadenoma of Aip/ mouse. Pituitary glands are depicted by white arrows.
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InAipmutation-positive somatotropinomas and prolacti-
nomas, the proliferation rates were 6.1 and 10.1%, re-
spectively. In wild-type prolactinomas, the fraction of
Ki-67-positive tumor cells was 3.6%. Hence, this result
supports the view of a more aggressive disease profile of
AIP mutation-positive tumors (138).
In a study of the histopathological characteristics of
normal pituitary and adenoma tissues, Leontiou et al. (67)
showed that in normal pituitary, AIP was present in GH-
and prolactin-positive cells but not in other cell types. In
sporadic pituitary adenomas withoutAIPmutations, AIP
immunostaining was present in all adenomas irrespective
of hormonal subtype; however, subcellular colocalization
of AIP and hormone was only seen with GH in soma-
totropinomas. In AIP mutation-positive tumors from
FIPA families (F269_H275dup and R304X mutations),
double immunofluorescence staining showed that AIP co-
localized with GH. On electron microscopy of normal
pituitary, Leontiou et al. (67) showed that immunogold
staining for AIP occurred only in GH- and prolactin-pos-
itive cells, and this staining was localized to the secretory
granules. Whereas in sporadic somatotropinomas immu-
nogold staining for AIP was also localized to the GH se-
cretory vesicles, in sporadic prolactinomas this associa-
tion between AIP and prolactin in secretory vesicles did
not exist (AIP immunogold staining was cytoplasmic, as
in corticotropinomas and nonfunctioning adenomas).
Sparse and dense granulation patterns on electronmicros-
copy have long been noted to associate with relatively
poor and good responses to somatostatin analogs, respec-
tively (143–145). Furthermore, cytokeratin staining of so-
matotropinomas in dot and perinuclear patterns mirror
the electron microscopic classifications of sparse and dense
granulation, respectively. Interestingly, dot pattern cytoker-
atin staining somatotropinomas tend to be larger sized, to
occur in younger individuals, and to have poorer responses
totestdoses/treatmentwithsomatostatinanalogs(146).This
combination of features echoes the findings ofAIP-mutated
somatotropinomas, suggesting an overlapping pathological
relationship, which is further strengthened by a high fre-
quency of sparsely granulated adenomas in somatotropi-
noma patients with AIPmutation in FIPA kindreds (67).
Recently, it has been suggested that AIPmay be a factor
in tumorigenesis and treatment responses of somatotropi-
nomas without AIP mutations. Jaffrain-Rea et al. (142)
demonstrated in a large series of AIP mutation-positive
and -negative tumors that AIP mRNA levels and immu-
nostaining intensities correlated with tumor phenotype
and aggressiveness. Somatotropinomas, independently of
their germline mutation status, showed lower AIP protein
levels in invasive tumors as compared with noninvasive
tumors. Supporting this notion, Gadelha’s group (147) in
Brazil recently noted that AIP immunostaining may be a
more useful marker of invasiveness than Ki-67 labeling.
Generally, patients with AIP-associated somatotropi-
nomahave poor response to the somatostatin analog ther-
apy (115). Kasuki et al. (148) studied whether the AIP
protein expression could act as a predictor of treatment
response to the somatostatin analog, octreotide, in AIP
mutation-negative somatotropinomas. They reported that
22% of patients with low AIP levels in tumor were con-
trolled with octreotide, whereas 65% of patients with
high AIP protein expression were controlled. When
both high AIP and somatostatin receptor 2 expression
were used as predictors, control was achieved in 79%of
patients. They concluded that the AIP protein expres-
sion alone is a good predictor of treatment response
octreotide.
Because the regulatory actions of somatostatin analogs
are mediated via five different somatostatin receptors,
Chahal et al. (126) studiedwhether the reducedexpression
of the somatostatin receptor 1–3 and 5 proteins could
explain the poor response to somatostatin analogs in AIP
mutation-positive tumors. They did not detect reduction
of somatostatin receptor subtypes, although the subtype 5
receptor had a somewhat higher expression in AIP-
mutated tumors as compared with sporadic somatotropi-
nomas (126). Importantly, AIP expression in tumors was
increased in patients that were pretreatedwith somatosta-
tin analogs before surgery. In that study, the effects of a
somatostatin analog on AIP expression were examined in
the GH3 rat somatomammotrope pituitary cell line. Oc-
treotide treatment increased expressionofAIPandZAC1.
Furthermore, overexpression of wild-type AIP was
found to increase ZAC1 expression, whereas silencing
of AIP reduced ZAC1 mRNA levels. Previously it was
shown that Zac1 acts downstream of somatostatin re-
ceptor subtype 2, and knockdown of Zac1 (via RNA
interference) prevented the effects of somatostatin an-
alogs. Also, immunoreactivity for ZAC1 in soma-
totropinomas has previously been shown to signifi-
cantly correlate with IGF-I normalization and tumor
shrinkage with somatostatin analogs (123–125). These
observations suggest that in somatotropinomas AIP
may be involved in the regulation of the action of so-
matostatin analogs via the ZAC1 pathway. Further-
more, this interplay between the AIP and ZAC1 genes
might also explain the statistically significantly reduced
response to somatostatin analogs in somatotropinoma
patients with AIP mutations (115).
C. Analysis of the biological functions of AIP
The AIP gene [also called the hepatitis B virus X-asso-
ciatedprotein 2 (XAP2) (149), aryl hydrocarbon receptor-
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activated protein 9 (ARA9) (150), or FK506-binding pro-
tein 37 (FKBP37) (151)] contains six exons, and it encodes
a cytoplasmic protein of 330 amino acids (37 kDa). The
AIP proteinwas originally identified by its interaction and
inhibition of the hepatitis B virus X protein 2 (152, 153).
AIP displays structural similarity to AIP-like 1 and the
immunophilin co-chaperones, FK506-binding protein (FKBP)
51 and FKBP52 (149, 150, 154). Despite homology with
immunophilins, AIP is not considered a true immunophi-
lin because it does not bind and mediate effects of
immunosuppressive drugs (155). AIP contains three
tetratricopeptide repeats and an -helix in the C-terminal
region, and this consensus tetratricopeptide repeat motif
mediates various intra- and intermolecular protein inter-
actions (156, 157). AIP can also self-associate and form a
multimeric complex (158), and theseAIPcomplexesmight
act as a reservoir for monomeric AIP that can be further
used in the formation of AHR complexes.
AIP is considered as being ubiquitously expressed,
but its expression levels vary considerably among dif-
ferent tissues (149, 153, 159). In normal pituitary, the
AIP protein is expressed in somatotrophs and lac-
totrophs, where it associates with cytoplasmic secretory
vesicles (67). Scattered AIP-expressed cells are detected
also in the pars intermedia (142). In sporadic pituitary
adenomas, AIP is expressed in all tumor types. In spo-
radic somatotropinomas, AIP colocalizes with GH in
the secretory vesicles, similar to normal somatotrophs.
In sporadic prolactinomas, corticotropinomas, and
nonfunctioning adenomas, AIP resides in the cytoplasm
(67). At present, the function of the AIP protein in nor-
mal pituitary or in pituitary adenoma cells is not known.
Although it is generally acknowledged that AIP germ-
line mutations predispose to pituitary adenomas, little
is known about the molecular mechanisms leading to
pituitary tumorigenesis. AIP has multiple cellular inter-
action partners (Fig. 6), and thus, AIP inactivation has
the potential to interfere with a wide spectrum of cel-
lular and environmental signals.
1. Xenobiotic signaling
The best-characterized AIP binding partner is AHR,
also known as the dioxin receptor. AHR is a ligand-acti-
vated transcription factor belonging to the basic-helix-
loop-helix (bHLH)/PER-ARNT-SIM homology region
(PAS) family. In the cytoplasm, AIP forms a complex with
AHR, two 90-kDa heat-shock proteins (HSP90), and the
co-chaperone p23 (159–163), although Hollingshead et
al. (158) suggested in their work that increased AIP levels
can displace the HSP90-associated p23 from the AHR
complex. AIP is involved in the cytoplasmic retention of
AHR and decreases its proteosomal degradation by pro-
Figure 6.
Figure 6. AIP interaction partners. Nodes represent proteins, with their shape indicating the functional class of the protein. The protein-protein
interaction network was generated with Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com).
Endocrine Reviews, April 2013, 34(2):0000–0000 edrv.endojournals.org 19
tecting it against ubiquitination (152, 160, 164, 165).
Upon ligandbinding, theHSP90dimer is released fromthe
complex, and AHR translocates into the nucleus, where it
undergoes a conformational change and interacts with
ARNT, also known as HIF1. AHR-ARNT complex reg-
ulates the transcriptionof detoxification enzymes bybind-
ing to the xenobiotic response elements (XREs) (Fig. 7)
(166, 167). This association is essential for transcriptional
activation of these genes in the presence of environmental
contaminants such as 2,3,7,8-tetrachlorodibenzo-p-di-
oxin and polycyclic aromatic hydrocarbons. There are
conflicting data about the role of AIP in regulating the
activity ofAHR. Some studies indicate thatAIP appears to
facilitate the transcriptional activity of AHR (149, 150,
168), whereas others suggest that AIP interaction inhibits
AHR activation (169–171). The reason for the contro-
versy regarding the effect of AIP interaction onAHR func-
tion may arise from species differences, tissue-specific ef-
fects, and the presence or absence of a ligand.
Exogenous AHR ligands, especially
dioxin, are known to inhibit cell prolif-
eration and induce cell cycle arrest (172),
and therefore, the role of AHR/ARNT
signaling was studied in AIP-mediated
tumorigenesis (141). Immunostaining re-
vealed that ARNT protein expression
was significantly reduced in human AIP-
associated tumors. In line with this find-
ing, the Aip mouse model revealed the
total lack of either ARNT or ARNT2
protein, but not both, in Aip-related pi-
tuitary lesions. Both proteins were al-
ways present in Aip-proficient pituitary
tumors (138). Also, a trend toward in-
creased nuclear expression of AHR was
detected. Supporting the nuclear accu-
mulation of AHR in the absence of func-
tional AIP, Nakata et al. (168) demon-
strated that small interfering RNA
silencing of Aip caused a weak nuclear
accumulation of AHR in ARNT-defi-
cient mouse hepatoma cell line. In con-
trast, in the work of Jaffrain-Rea et al.
(142), no nuclear expression ofAHRwas
detected in AIP-associated pituitary tu-
mors. Such a discrepancy might arise
from antibody epitope differences and
the type of mutations studied.
Down-regulation of ARNT proteins
in AIPmutation-positive adenomas may
disturb the AHR/ARNT complex forma-
tion and lead to aberrant expression of
xenobiotic response target genes (Fig. 8A). To study this
aspect, expression of p27(Kip1), was studied in human
AIP-deficient pituitary tumors (141). The expression of
p27(Kip1) protein was, however, found to be equal in
AIP-deficient and -proficient pituitary tumors (141). Al-
though germline mutations in CDKN1B gene encoding
p27(Kip1) causeMEN4syndrome, suchmutationsarenot
associated with pituitary tumorigenesis in FIPA (173–
175). Thus, it is not likely that p27(Kip1), acting via xe-
nobiotic signaling would contribute toAIP-associated tu-
morigenesis. Nevertheless, dioxin-related compounds
interfere with the body’s endocrine system and may pro-
duce adverse developmental, reproductive, neurological,
and immune effects (176). In the study of Pesatori et al.
(177), where the authors analyzed the occurrence of pi-
tuitary adenomas in the Seveso population in Italy, after a
severe 2,3,7,8-tetrachlorodibenzo-para-dioxin exposure
accident in 1976, no statistically significant increase in the
prevalence of pituitary tumors was found. However, an
Figure 7.
Figure 7. A schematic figure of the xenobiotic signaling. AHR exists in a dormant state in
cytoplasm in association with a complex of HSP90, AIP, and the co-chaperone p23. Upon
ligand binding, AHR is activated through conformational change and translocates to the
nucleus. It forms a heterodimer with ARNT. The heterodimer binds to the XRE and alters
expression of genes involved in the metabolism of xenobiotic agents.
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increased prevalence of acromegaly has been observed in
highly polluted industrial areas (178), leading to the sug-
gestion that suchpollutantsmay act in someway to induce
or promote pituitary tumorigenesis.
2. Other AHR-regulated signaling cascades
Although the best-described AHR signaling pathway is
the xenobiotic response, recent findings suggest that AHR
is a multifunctional protein involved in the regulation of
other signaling cascades and undertakes cross talk with
several other pathways. Perhaps the best-characterized
cross talk with the AHR pathway concerns steroid hor-
mone receptors. AHR is involved in the regulation of es-
trogen response signaling, mediated by estrogen receptors
 and  (ER and ER) (179, 180). Also, the het-
erodimerization partners of AHR, ARNT and ARNT2,
coactivate both ER and ER (181). The cross talk be-
tween the AHR/ARNT and ER signaling is interesting be-
cause the estrogen receptor signaling pathway is known to
act in the biosynthesis and secretion of hormones of the
anterior pituitary and to stimulate the proliferation of lac-
totropes and gonadotropes (182). Moreover, estrogen-
induced transcriptional targets include growth factors
[e.g., IGF, epidermal growth factor (EGF), TGF, and vas-
cular endothelial-derived growth factor], and several on-
cogenic proteins (c-myc, c-fos, erb, c-myb, pttg) (183).
More recently, it has been demonstrated that AIP acts as
a negative regulator of estrogen signaling through the in-
teraction with ER (Fig. 8A) (184). Thus, AIP may have a
role in preventing cell proliferation in ER-dependent
tumors.
Apart from their AHR interaction, ARNTandARNT2
are also binding partners of hypoxia-inducible factor 1
(HIF1). The HIF1-ARNT complex binds to hypoxia-
responsive elements andactivates the transcriptionofhyp-
oxia response target genes (Fig. 8A) (185). This complex
is involved in the adaptive response to oxygen deprivation
in tumor cells, and it controls the up-regulation of a num-
berof factors that are important for solid tumor expansion
(185–189). To study the impact of the AIP tumorigenesis-
associatedARNTprotein imbalance on estrogen and hyp-
oxia responses, expression of ER andHIF1was studied
in human and mouse AIP-deficient pituitary adenomas
(138, 141). Immunostaining showed that the ER and
HIF1 protein intensities were uniform in AIPmutation-
positive and -negative tumors. These findings suggest that
estrogen and hypoxia responses seem to be functional and
that these signaling cascades are not necessarily involved
in AIP-mediated tumorigenesis (138, 141).
Both ARNT proteins interact also with the single-





Figure 8. A, Role of AHR-ARNT heterodimer in transcriptional regulation of xenobiotic, hypoxia, and estrogen signaling. B, Role of AIP in regulation
of cAMP signaling via G-proteins and C, via PDEs. HRE, Hypoxia response element; ERE, estrogen response element.
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191). SIM 1 and 2 belong to the basic helix-loop-helix/
Per-Arnt-Sim homology (bHLH/PAS) protein family and
require heterodimerization with either ARNT or ARNT2
to function. In the absence of Sim1 function, the paraven-
tricular nucleus and supraoptic nucleus of the hypothal-
amus fail to develop. Both the paraventricular and su-
praoptic nuclei play important roles in modulating
hormone secretion of the pituitary to maintain homeosta-
sis (192). The Sim2 gene is required to produce a full com-
plement of anterior hypothalamic cells expressing TRH
and somatostatin (193, 194). Thus, it is possible that ab-
errant ARNT/ARNT2 function might have an impact on
SIM1/2-controlled development and regulation of the pi-
tuitary/hypothalamic axis in AIP-associated pituitary
tumorigenesis.
Of late, it has become evident that AHR also has a role
in controlling the cell cycle. AHR appears to act as both a
pro-proliferative and an anti-proliferative gene, depend-
ing on the cell type. Some studies indicate that AHR can
promote cell cycleprogression in theabsenceof exogenous
ligands (195, 196), whereas more recent studies are sug-
gesting thatAHRmay functionasa tumor suppressorgene
that becomes silenced during the tumor formation, e.g., in
prostate and liver tumorigenesis (197, 198). This contro-
versy regarding the role of AHR in tumorigenesis (pro-
proliferative vs. anti-proliferative) may arise from tissue
specificity and the absence or presence of ligand (199). For
the most part, the exact role of AHR in signaling cascade
responsible for modulating the cell cycle is unknown. One
mechanismbywhichAHRhas anti-proliferative potential is
through the interaction with the retinoblastoma (RB1) pro-
tein. In thepresenceofmitogenic signals,AHRinteractswith
RB1and cooperates in repressing cell cycle progression, par-
ticularly intheG1toSphasetransition(200). It isnoteworthy
that loss of the RB1 chromosomal region or promoter hy-
permethylationof thegeneappears toberelatedtoaggressive
pituitary adenomas and carcinomas (201, 202).
Although it has been shown that low levels of AIP cor-
relate with low levels of AHR in pituitary tumors (132),
relatively little is known about the function of AHR in
pituitary tissue. However, the AHR-ARNT imbalance as-
sociated with AIP-related tumorigenesis, as well as the
role of AHR in the regulation of cell cycle progression,
makes AHR an interesting candidate to be involved in the
AIP-mediated tumorigenesis. Moreover, AHR has been
found to be sensitive to cAMP signaling (169, 203). The
ability of cAMP to modulate the biological function of
AHR is very intriguing because cAMP is known to play a
central role in the tumorigenesis of somatotropinomas.
3. Role of AIP in the regulation of cAMP signaling
cAMP signaling is a large network that generates in-
teractions between different pathways and integrates sig-
nals from distinct receptors (204). In certain tissues, such
as in thyroid, adrenal cortex, and pituitary somatotroph
cells, cAMP stimulates cell proliferation, and aberrant
cAMP signaling is directly implicated in several diseases
including the genesis of somatotropinoma (205).
Guanine nucleotide-binding proteins (Gproteins) form
a large family of signal-transducing molecules. They are
heterotrimeric proteins formed by G-, G-, and G-sub-
units. Ligand-receptor binding switches G protein to an
active state and permits G activation of second messen-
ger signaling cascades. G proteins communicate signals
from many hormones, neurotransmitters, and other sig-
naling factors and have an essential role in the regulation
of cAMP levels. Alteration of the cAMP-protein kinase A
pathway is known to be involved in somatotrope tumor-
igenesis via oncogenic somatic mutations of the -subunit
of the stimulatory guanine nucleotide-binding protein
(GNAS, also known as Gs) (MIM: 102200). It has been
estimated that up to 40% of sporadic somatotropinomas
harbor a somatic mutation in GNAS (206–210). High
cAMP levels have also been linked to the pathogenesis of
other syndromic conditionswith pituitary adenomas such
asMcCune-Albright syndrome (MIM: 174800) andCNC
(MIM: 160980) (211, 212). Although G proteins are
known to be involved in the cAMP response regulation
and share highly conserved primary structure, at present
GNAS is the only G protein gene that has been identified
as a target formutations that are unequivocally associated
with pituitary tumorigenesis (205).
AIP interacts with two G proteins, G13 and Gq.
These interactions were shown to inhibit the interaction
between AHR and AIP (168). The G13 signal activation
was also found to cause ligand-independent nuclear trans-
location of AHR (Fig. 8B), and similar to cAMP-mediated
nuclear AHR, the G13-induced nuclear AHR adopts a
structure that prevented a formation of active transcrip-
tional complex with ARNT (168, 169). Additionally, it
has been demonstrated thatG13 is able to regulate cAMP
concentration by cooperating with GNAS (213, 214),
thereby providing a possible mechanism for pituitary tu-
morigenesis related to AIP germline mutations.
Phosphodiesterases (PDEs) are a large family of en-
zymes that degrade and deactivate cAMP. Thus, the find-
ing that AIP interacts with PDE2A and PDE4A5 provides
an additional mechanism by which AIP might contribute
to the genesis of somatotropinomas (169, 170, 215).
PDE2A hydrolyzes both cAMP and cGMP (216). The in-
teraction of PDE2A with AIP is intriguing because the
AIP-PDE2A interaction has been shown to inhibit cAMP-
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induced nuclear translocation of AHR (Fig. 8C) and to
reduce the expressionofAHR-regulated target genes (169,
215). Thus, it is possible that the lack of AIP can lead to an
aberrant expression ofAHR target genes through elevated
cAMP levels, a hallmark of somatotropinomas. MacKen-
zie et al. (217) found that GH-mediated differentiation of
3T3-F442A cells was accompanied by increased cAMP
PDE activity by a specific PDE4A isoform that they called
PDE4A5. AIP binding to the cAMP-specific PDE4A5 in-
hibited its enzymatic activity (Fig. 8C) and attenuated the
ability of cAMP-dependent protein kinase to phosphory-
late PDE4A5 (170). As a method to assess the functional
validity of the effects of specific germline mutation ofAIP
seen in FIPA families and simplex patients, many muta-
tions completely abolished or significantly attenuated the
interaction of AIP with PDE4A5 (67, 86). However, be-
cause elevated cAMP levels are associated with pituitary
tumorigenesis, it is unclear how AIP could exert its tumor
suppressor action through PDE4A5.
4. Other AIP-associated proteins and implications in
AIP-mediated tumorigenesis
The rearranged during transfection (RET) proto-onco-
gene is a transmembrane tyrosine kinase. In the absence of
ligand, RET induces apoptosis (218). Gain-of-function
mutations of RET are associated with MEN2A and
MEN2B (MIM: 171400 and 162300), and familial med-
ullary thyroid carcinoma (MIM: 155240). Loss-of-func-
tion mutations of RET predispose to Hirschsprung’s dis-
ease (MIM: 142623) (219–221). In the pituitary, RET is
expressed in somatotropes where it is associated with ap-
optosis and differentiation and stimulates expression of
pituitary transcription factor-1 and p53 (218). Among pi-
tuitary tumors, RET is expressed in somatotropinomas
and a subset of corticotropinomas (222). AIPwas recently
found to interact with the proapoptotic domain of RET
(223). However, pathogenicAIP andRETmutations that
were introduced into cells did not impair the AIP-RET
interaction. In addition, no RET mutations have been
found in somatotropinomas or FIPA families (223, 224).
Survivin belongs to the family of inhibitors of apoptosis.
The survivin-AIP-HSP90 complex stabilizes survivin, but
in the presence of RET, AIP is unable to bind and protect
survivin from degradation, leading to enhanced apoptosis
(223, 225). Although there is cross talk between RET and
survivin and both of the proteins are involved in the reg-
ulation of apoptosis, the relevance of these proteins in
pituitary tumorigenesis remains uncertain.
Trivellin et al. (226) recently highlighted yet another
manner in which AIP may be involved in pituitary tumor
pathology, namely via regulation by the micro-RNA-107
(miR-107). They noted that AIPwas a target of miR-107
via a 6-mer site 65–70 bp downstream of the AIP stop
codon on the 3	 untranslated region of AIP. This mi-
croRNA was capable of inhibiting AIP expression, and it
was suggested that the overexpression of miR-107 in pi-
tuitary adenomas could explain the decreased AIP expres-
sion seen particularly in aggressive somatotropinomas.
This effect may differ in other pituitary tumor subtypes,
such as nonfunctioning tumors, whereAIP expression lev-
els are possibly less important in determining pathological
behavior.
The EGF receptor (EGFR) is a transmembrane glyco-
protein, a member of the protein kinase superfamily. AIP
was reported to interact with EGFR in a large-scale inter-
action screen (227). However, the AIP-EGFR interaction
status is uncertain because this interaction has not been
further validated. EGFR is activated by binding of its spe-
cific ligands, including EGF and TGF. Both of these li-
gands act as mitogens in endocrine pituitary cells. Recent
work fromMelmed’s group has built a body of significant
evidence that indicates that targeting EGFR is a valuable
potential therapy for pituitary adenomas (8–10, 228). It is
also noteworthy that dioxin-activated AHR can trigger
sequential activation of EGFR and ERK, leading to the
increased expression of TGF (229). Thus, the confirma-
tion of AIP-EGFR interaction would be important, given
the aggressive phenotype and relative therapeutic resis-
tance associated with AIP mutation-related pituitary ad-
enomas (115).
AIP is involved in various nuclear receptor signaling
pathways. In addition to AHR and ER, other nuclear
receptors capable of binding AIP include peroxisome pro-
liferation-activated receptor (PPAR), thyroid hormone
receptor 1 (TR1), and glucocorticoid receptor (GR).
PPAR regulates the expression of genes involved in fatty
acid -oxidation and is a major regulator of energy ho-
meostasis. The cytosolic PPAR-HSP90-AIP complex has
a repressor effect on PPAR (230, 231). TR1 is a nuclear
hormone receptor and mediates the biological activity of
thyroid hormone. AIP silencing is known to abolish the
TR1-mediated thyroid hormone expression (232). GR
interactswithAIP throughHSP90.The effect ofAIPon the
GR signaling is inhibitory because AIP delays the nuclear
accumulation of GR. In the nucleus, GR regulates genes
controlling development, metabolism, and immune re-
sponse. LOH has been observed at the GR gene in about
one third of ACTH tumors, suggesting a possible role of
GR at least in corticotrope tumorigenesis (233, 234).
AIP was first identified as a partner of the X antigen of
the hepatitis B virus, a human DNA virus causing acute
and chronic hepatitis. AIP seems to act as a negative reg-
ulator of theXprotein, and the interactionmayhave a role
in the hepatitis B virus pathology (149). Another viral
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protein that interacts with AIP is Epstein-Barr virus en-
coded nuclear antigen-3 (235). It has been suggested that
the AHR pathway can be involved in virus-induced cell
transformation (236). AIP has been reported to interact
with the translocase of the outer membrane of mito-
chondria 20, a subunit of a translocator complex that
imports mitochondrial pre-proteins into mitochondria
(237). In addition to HSP90 binding, AIP can also in-
teract with another heat-shock protein, the heat-shock
cognate protein 70 (165). AIP interaction with the car-
diac troponin I-interacting kinase (238) is intriguing
because a recent study by Lin et al. (133, 134) showed
that Aip knockout mice died during embryogenesis due
to cardiac malformations.
As described above, AIP has multiple interaction part-
ners (Fig. 6).Through these proteins, alterations innormal
AIP function has the potential to affect a large number of
different pathways and signaling cascades. It appears that
a number of these interacting partners are potential can-
didates to promoteAIPmutation-related pituitary tumor-
igenesis, particularly the role of AIP in the regulation of
cAMP levels and the cross talk between AHR and cAMP
pathways.Work based on theAip knockoutmousemodel
and humanpituitary tumors is underway to determine the
proteins andmolecular mechanisms underlying genesis of
AIP-associated pituitary tumorigenesis. Characterization
of these proteins and signaling cascadesmight reveal novel
therapeutic opportunities for the patients with these rel-
atively treatment-resistant pituitary tumors.
V. Genetic Testing for AIP in Selected Pituitary
Adenoma Populations
A. Defining the ideal testing populations
The main aim of genetic testing for AIP germline mu-
tations is to identify those at risk of potentially aggressive
pituitary adenomas and permit early diagnosis of such
adenomas at the microadenoma and noninvasive stage,
where treatment is more likely to be effective or curative
(239). While AIP mutation-related pituitary adenomas
appear to be associated with a decreased rate of control
with medical therapies (somatostatin analogs and dopa-
mine agonists), not enough is known about the molecular
pathways involved in AIP mutation-related pituitary tu-
morigenesis to permit specific choices ofmedications to be
recommended. Therefore, AIP mutation-positive pitu-
itary adenomas should be managed according to current
guidelines for acromegaly, prolactinoma, etc. (240–242).
Published results to date provide firmevidence thatAIP
mutation screening in unselected general pituitary ade-
noma populations is not strictly justifiable to identify af-
fected patients. Two large studies in more than 400 sub-
jects each have shown overall rates of AIP germline
mutations of about 4% of unselected sporadic cases (99,
101). However, taking together these results and those
from subgroup studies focused on acromegaly, pediatric
studies in sporadic and syndromic cases and the clinical
characteristics of large cohorts of AIP mutation-positive
FIPA cases, some approaches to effective AIP mutation
screening become apparent (67, 71, 75, 84, 86, 89, 90, 93,
95–101, 104–109, 115, 116, 118, 127, 142, 243, 244).
The highest likelihood of identifying AIP mutation-posi-
tive cases is among patients with gigantism,who comprise
25% of those with AIP mutations overall and a third of
AIP-mutated somatotropinomas. In particular, those pa-
tientswith gigantism in a familial settingof gigantismhave
the highest probability of having an AIP mutation (85).
The PAP associated withAIPmutations leads to the early
development of large pituitary adenomas, usually soma-
totropinomas, so consistent excessive gain in height in
children and adolescents when a pituitary adenoma is sus-
pected should lead the clinician to consider AIP testing.
Morepractically, forAIPmutation-positive children from
families with a known AIP mutation, monitoring abnor-
mal gain in height should be an integral part of clinical
surveillance.
Up to 20.5% of pediatric patients (those aged less than
18 yr at diagnosis) with a macroadenoma have been re-
ported to be AIP mutation positive (108). Macroadeno-
mas occurring in young adults (30 yr old) also appear to
be a valuable indicator of a possible AIP germline muta-
tion (11%) and may in the future represent a condition in
which routine screeningmay be effective. The next readily
identifiable group in which focusedAIP genetic screening
could be beneficial is among FIPA cohorts. Combining the
results ofmajor national and international collaborations,
about 20% of FIPA kindreds are AIP mutation positive,
with the overall rate being only slightly higher in homo-
geneous vs. heterogeneous kindreds (22.8 vs. 16.7%).
Many different mixtures of pituitary tumor types are now
associated with AIP mutations in the FIPA setting, al-
though the majority of patients withAIPmutations come
from families with somatotropinomas, somatolactotropi-
nomas, prolactinomas, and NFPA.
B. Disease penetrance
As originally described, germline AIP mutations were
associatedwith a lowpenetrance of pituitary adenomas in
affected families in Finland (84). Since then, a large num-
ber of kindreds with AIP mutations have been reported
(67, 71, 86), and some particularly large families have
been studied genetically and clinically (84, 89, 90). In gen-
eral, the larger andmore completely studiedkindreds have
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a penetrance that is in the low range (20% penetrance
approximately). From the studies of FIPA cohorts to-
gether, the penetrance rate is more variable. Based on ini-
tial studies on selected families, a penetrance rate of up to
50% or more was suggested (67, 69). Based on a calcu-
lation that took into account affected patients, obligate
carriers, and half of the subjects with a 50% risk of in-
heriting a mutation, Igreja et al. (86) reported a mean
penetrance rate of pituitary tumors in AIPmutation-pos-
itive FIPA families of 42  21%. These figures varying
from 20–66% can be explained by a number of potential
factors. First,many FIPAkindredswere initially described
as clusters of closely related individuals, andAIP sequenc-
ing in these families also tended to discover clusters of
affecteds and carriers that led to relatively high penetrance
rates. Expansion of kindred studies to second- and third-
degree relatives can serve to lower penetrance rates. In
contrast, certain FIPA kindreds with large numbers of af-
fected patients (five ormore) have been described (67, 86).
Such kindreds show that there appears to be an inherent
variability in the penetrance, with some families having
many affected subjects and a low number of carriers,
whereas other families with similar truncating AIPmuta-
tions have a low number of affecteds among a wealth of
unaffected adult carriers. In addition, numerous cases of
familial mutations with only a single affected patient have
been discovered (“simplex” cases), whereas other unre-
lated families with the same mutation (R304X, R271W)
have multiple members with aggressive, early-onset mac-
roadenomas. These findings can be explained at least in
part by ascertainment bias; the families with striking oc-
currenceof adisease enter genetic studiesmuchmoreoften
than more subtle clusters. At this time, the penetrance of
AIPmutations in theFIPAsetting canbe consideredas low
to perhapsmoderate penetrance. The variability raises the
possibility that, in addition to simple chance, some un-
known endogenous genetic factors (i.e., other gene vari-
ants/mutations or modulators/repressors) or extraneous
environmental effects (i.e., toxins, dioxin, etc.) related to
or separate from AIP and its molecular pathway play a
role in determining which mutation carriers develop pi-
tuitary adenomas.
One important feature of AIP mutation-positive FIPA
kindreds is thatofphenocopy inwhichamemberof aFIPA
kindred has a pituitary adenoma but has a normal AIP
sequence, unlike the other affected members of the family
that have an AIP mutation (73, 87). Phenocopies are of
particular importance in the setting of FIPA because in the
general population pituitary adenomas occur in about
1:1000 people, whereas incidental tumors (without clin-
ical correlates) occur in more than 15% of individuals (1,
245). Hence, the genetic investigation of AIP mutation-
positive FIPA kindreds can be confounded by the presence
of such phenocopies and can lead to unnecessary study
and follow-upof nonmutation carriers. The challenges are
illustrated in Fig. 9, in which a kindred presented as a
three-member heterogeneous FIPA family, with soma-
totropinomas in father and son (cases III-6 and IV-7, re-
Figure 9.
Figure 9. Phenocopy NFPA in the setting of an AIP mutation-positive FIPA kindred with acromegaly.
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spectively) and an NFPA in case III-2, the brother of case
III-6. The tumor size at diagnosis in case III-6 in the 1960s
was unknown, although the patient was relatively young
(29 yr old) at diagnosis and had suffered from symptoms
since adolescence. His son was diagnosed in his early 40s
with acromegaly due to a microadenoma. Case III-2 de-
veloped a pituitary macroadenoma in his 60s. Although
both father and son with somatotropinomas were found
to have the p.R271W AIPmutation, repeated sequencing
of theAIPgene in case III-2wasnormal.Hewasdiagnosed
as having a phenocopy NFPA, thereby markedly curtail-
ing the screening process in generation IV.
C. Toward integrated genetic screening in
pituitary adenomas
Although AIP mutations are associated with isolated
pituitary tumors, genetic testing cannot be viewed in iso-
lation from syndromic forms of endocrine neoplasia. In-
deed, investigationof thepatientwith apituitary adenoma
should always take account of the possibility of a genetic
background and related disease in other tissues. Multiple
germline gene mutations are associated with an increased
predisposition to pituitary tumor development, but these
are usually part of a syndrome displaying additional di-
agnostic features. The occurrence of multiple individuals
with isolated pituitary adenomas in the setting of familial
MEN1 and CNC in the absence of other cardinal skin,
vascular, or neoplastic signs after a thorough clinical an-
amnesis is likely to be very rare. Indeed, only 2%ofMEN1
patients only had pituitary adenomas, and familialMEN1
caseswith only pituitary adenomas are, to our knowledge,
unknown (14). However, it is important to note that be-
cause approximately 17%ofMEN1patients presentwith
pituitary adenomas, specific efforts must be made to clin-
ically and biochemically search for other disease manifes-
tations. As such, an initial division of pituitary adenoma
patients into those with or without any history of syn-
dromic features or family history is a practical first step
before considering genetic testing (Fig. 10). Surveillance
for MEN1 can follow already agreed guidelines and rec-
ommendations, which have been recently and very com-
prehensively updated to take into account discrimination
between MEN1 and other conditions like FIPA (246–
248). In familial cases of MEN1, pituitary adenomas are
significantlymore commonly seen than in sporadicMEN1
(59 vs. 34%). As noted above, it is only in exceptional
cases that MEN1 is characterized by only a pituitary ad-
enoma in the absence of other cardinal syndromic features
(e.g., parathyroid disease). Both FIPA and MEN1 have a
large proportion of females with prolactinomas. Pituitary
tumors inMEN1differ significantly fromsporadic tumors
(including prolactinomas) in terms of more frequently be-
ing macroadenomas (85 vs. 42%) (14). Probably related
to this larger size, pituitary tumors in MEN1 are also sig-
nificantlymore likely than sporadic tumors to cause symp-
toms and signs due to local tumor effects. In FIPA, patients
are much more likely to present with somatotropinomas
(14, 65, 69).
CNC is associated with a typical spectrum of syn-
dromic features, andparticular attention shouldbepaid to
these, while recalling that pituitary adenomas occur in
only a minority of CNC cases, and familial presentation
limited only to acromegaly is not known in this condition
at this time (46). For patients with pituitary adenomas
with other MEN1-like features, but who do not have a
MEN1mutation,CDKN1Bmutation screening shouldbe
considered (249). However, in the setting of FIPA,
CDKN1B does not play a clinically relevant role (175).
New associations have been made between pituitary ad-
enomas and endocrine neoplasia genes previously not
thought to be involved in pituitary tumorigenesis, such as
SDHD as recently reported by Xekouki et al. (250). In-
vestigation of this and other potential associations may
expand thenumber and complexity of testing in the setting
of endocrine neoplasia syndromes.
Specifically focusing on the investigation of FIPA, AIP
testing should be considered in all kindreds, irrespective of
pituitary tumor types in the family. In FIPA kindreds that
are negative onAIP sequencing, deletions have been dem-
onstrated using MLPA, and this method should be con-
sidered as a second line of screening. For AIP mutation-
negative FIPA families (80% of cases), academic research
projects are currently under way to discover novel genetic
causes, but no current candidates canbe recommended for
further study in the clinical setting at present. For patients
without FIPA or syndromic features suggestive ofMEN1,
CNC, etc., genetic testing for AIP mutations can be con-
sidered in a number of situations. Because AIPmutations
are seen in up to 11% of pituitary macroadenomas diag-
nosed before the age of 30 and about 20% of those with
macroadenomas under the age of 18, AIP sequencing
should be strongly considered in this readily defined sub-
group (108). Also, gigantism is common in AIP-mutated
patients, andAIP testingwould seem clinically reasonable
in such patients with established gigantism and also in
young patients with excessive height gain in association
with a pituitary adenoma. There has also been a sugges-
tion that pituitary apoplexy is a feature of AIP-mutated
pituitary adenomas, reflecting their large size and poten-
tially rapid size expansion; a strict association between an
increased risk of apoplexy and AIP mutation status re-
mains to be demonstrated. Finally, among patients with
somatotropinomas, resistance to medical therapy has
been reported for AIP mutation-related adenomas (67),
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which leads to statistically significantly lower hormonal
and tumor size responses as compared with AIP intact
controls (115). Prolactinomas, although less frequent than
somatotropinomas in this setting, also appear to be large
and relatively resistant to dopamine agonists (115). In pa-
tients with sporadic pituitary macroadenomas, resistance
to therapy may be another suggestive feature to guide of-
fering genetic testing forAIPmutations, although specific
AIP mutation prevalence studies in resistant populations
are awaited.
It is important to note that in cases where an AIP mu-
tation is diagnosed in a sporadic case, many families that
agree to genetic testing display asymptomatic mutation
carriers. The variable low to moderate penetrance of pi-
tuitary adenomas among AIP mutation carriers compli-
cates the process of screening because clinically affected
patients are in the minority and currently most of our
experience is with patients that have already developed
macroadenomas. The issue of when to begin clinical and
genetic surveillance in relatives of known carriers/affect-
edswithAIPmutations isone thatmustbe informedby the
fact that presentation in childhood/adolescence is a typical
feature of the illness (90, 101, 104, 106, 108, 115). A
patient as young as 6 yr has been diagnosed with an AIP
Figure 10.
Figure 10. Schematic of suggested clinical decision tree to integrate AIP genetic testing into existing testing strategies. The decision tree is based
on the presence or absence of typical syndromic features that suggest known diseases such as MEN1, CNC, and McCune Albright syndrome
(MAS), which have established genetic testing for known causative genes. Point 1, Established syndromes like MEN1 and CNC are being
joined by newer associations of pituitary adenomas with other endocrine tumor types, such as pheochromocytoma in the setting of succinate
dehydrogenase subtype gene mutations (250). Ongoing advances in this field will clarify the relative frequency of such associations and the need
to integrate testing into standard clinical investigation. Point 2, In CNC, a proportion of patients are negative for PRKAR1A mutations, and another
locus on chromosome 2 has been suggested (252). Point 3, MEN4 due to CDKN1B mutations is a rare but emerging condition with pituitary
adenomas as part of the spectrum. CDKN1B testing in patients with pituitary adenomas should be limited in the clinical setting to those with
associated syndromic features of endocrine or other tumors and negative sequencing for MEN1 mutations (174, 244). Other rare mutations in
cyclin-dependent kinases have also been noted infrequently in MEN1-like conditions, but the study of these remains in the research realm (253).
Point 4, In the setting of FIPA, the PAP due to AIP germline mutations accounts for about 20% of kindreds. For FIPA kindreds that are AIP
mutation negative on sequencing, MLPA should be considered to detect more extensive deletions. To date, other genes have not been identified
to cause FIPA. Syndromic conditions like MEN1 and CNC do not frequently present as isolated pituitary adenomas in the absence of other features
such as hyperparathyroidism. An exception may be young patients with apparently sporadic pituitary macroadenomas, with recent information
from Cuny et al (254) suggesting that MEN1 gene sequencing is a valuable investigation in that population. Therefore, in the verified FIPA setting
and in younger patients with aggressive pituitary adenomas, AIP testing may be considered as the first genetic test to be discussed, as long as
MEN1 and CNC are ruled out clinically and by simple biochemical testing (e.g., absence of hypercalcemia or cortisol secretion abnormalities).
Endocrine Reviews, April 2013, 34(2):0000–0000 edrv.endojournals.org 27
mutation and pituitary macroadenoma, with additional
signs and symptoms for the preceding 12–24months (90).
Although screening to date in mutation carriers is still
relatively scant, work in larger families has identified car-
riers with pituitary microadenomas or other abnormali-
ties of maturation (89, 115). These patients remain under
surveillance, but information on the rate and characteris-
tics of pituitary tumor evolution is limited and remains an
important unanswered clinical question for the future.
For those individuals that are at risk for carrying anAIP
mutation that has been diagnosed in a relative, the ideal
step is to offer genetic screening after appropriate coun-
seling and explanation of the benign nature of pituitary
adenomas, the possible benefits of early diagnosis, and the
current understanding of the variable penetrance. Genetic
screening for a familial AIP mutation has the benefit of
being able to rule out noncarriers definitively, thereby
avoiding unnecessary stress. Given thatmore than 75%of
cases have been diagnosed before the age of 30, screening
efforts in new kindreds should ideally beweighted toward
children and young adults in the first instance. Mutation
carriers or potential carriers that decline initial genetic
testing should be offered a thorough clinical assessment by
an endocrinologist, accompanied by basal testing of GH/
IGF-I and prolactin. Carriers with any signs or symptoms
suggestive of a pituitary adenoma or those that express an
interest in undergoing imaging should have a baseline pi-
tuitary MRI performed. Mutation carriers that are with-
out clinical signs or hormonal abnormalities and have a
normal MRI should be followed up, although no mini-
mum period can be recommended based on a lack of ev-
idence. The investigation of potential pediatric/adolescent
AIPmutation carriers is of particular importance because
these patients have added complications in terms of inter-
preting normal growth spurts and pubertal changes while
actively surveying for suggestive endocrine abnormalities.
Should genetic testing be permitted by a parent/guardian,
this has been performed in children as young as 2 yr of age,
with the benefit of being able to reassure parents if the
familial mutation is not found. For carriers or those not
wishing to have genetic testing performed in their child,
care should be taken to actively seek out clinical signs/
symptoms suggestive of somatotrope or lactotrope over-
activity or tumor impingement on local structures (vision,
recurrent headache) and to carefully examine growth ve-
locity. In those with symptoms suggestive of a pituitary
adenoma, imaging and hormonal testing should be per-
formed as soon as possible because tumors as large as
35–38 mm have been diagnosed in patients aged 10 or
younger.
D. Follow-up in the setting of FIPA and AIP
mutation carriers
There are no established guidelines to outline the rec-
ommended follow-up for unaffected AIP mutation carri-
ers. For those with no symptoms or evidence of pituitary
abnormality, it is important to inform the individual of
symptoms that may be suggestive of a new endocrine ab-
normality and to encourage the subject to return should
such symptoms occur. It is probably wise to review the
subject after a year, and in the absence of new clinical
features, the subject can be returned to their regular phy-
sician’s care. For pediatric and adolescent carriers, fol-
low-up with the pediatrician for growth or other endo-
crine disorders is recommended, and rapid referral back to
the pediatric endocrinologist upon the appearance of rel-
evant symptoms should be emphasized.
The more challenging situation is the AIP mutation
carrier that has a microadenoma onMRI and has no clin-
ical signs/symptoms and normal hormonal screening. It is
difficult in such cases todeterminewhether this patient has
an incidentaloma that is stableorhasanAIP-relatedgrow-
ing pituitary adenoma. In adult patients, in the absence of
new symptoms or hormonal abnormalities, there is prob-
ablynoneed to repeat anMRIuntil 12monthshavepassed
since the baseline scan. Given the usual early appearance
of these tumors, often in childhood/adolescence, and the
lack of knowledge about their growth potential, in young
patients a follow-upMRImaybemoreadvisable6months
after diagnosis inAIPmutation carriers. Should the tumor
remain as a stable microadenoma over that period, then
clinical and hormonal follow-up can probably remain in
place on an annual or biannual basis as long as no change
in endocrine status occurs. In such cases, the usual balance
of definitive surgical cure over medical therapy would
have to be made according to the individual tumor type
and the clinical status of the patient. Follow-up of and
decisions regarding intervention in patients with diag-
nosed AIPmutation-related pituitary adenomas does not
differ from that of sporadic pituitary adenoma patients.
For FIPA patients without AIP mutations, the fol-
low-up recommendations are relatively more difficult to
codify in the absence of a causative gene. Efforts should be
made to clearly identify patients within the kindred who
may be harboring a pituitary adenoma, based on family
history and careful anamnesis in collaboration with pa-
tients and relatives. Those individuals with specific symp-
toms or signs of a pituitary adenoma should, like any pa-
tient with suggestive symptomatology, undergo relevant
hormonal and/or imaging studies. Follow-up manage-
ment ofAIP-negative subjects with pituitary adenomas in
the setting of FIPA does not at this time differ from those
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with sporadic tumors and should, where possible, be
guided by international consensus guidelines.
VI. Future Directions
The advent of FIPA and the discovery of AIP as a gene
involved in inherited pituitary adenomas have refocused
attention on the role of familial and genetic factors in the
pituitary adenoma population. However, despite the ad-
vancesmade, approximately 80%ofFIPA families remain
without a genetic explanation. Ongoing work in AIP-
negative FIPA families at a genomic level may highlight
novel loci and eventually causative genes. In parallel, there
may be value in studying the potential role of other endo-
crine neoplasia-related genes, such as the SDHx genes, to
discover whether their newly reported links to pituitary
tumorigenesis play a role in causation of the FIPA pheno-
type (250, 251). Because FIPA comprises 2–3% of pitu-
itary adenomas at certain tertiary referral centers (65),
improved questioning about family history of pituitary
adenomas and other endocrine cancers will be helped by
greater awareness of FIPA and the role ofAIP in causation
of pituitary adenomas in families and young patients.
With respect to AIP, improved understanding of the pen-
etrance related to the PAP induced by AIPmutations will
be necessary to permit accurate counseling of patients and
to improve genetic diagnosis of mutation carriers when
tumors are still relatively small. Also, penetrance studies
will help to answer whether rare tumor associations seen
in FIPA families with AIP mutations occur by chance or
form a predictable but infrequent association.
Study of the evolution of pituitary adenomas in as-
sociation with AIP mutations from their early stage is
necessary to determine what pathway they follow (for
example, a hypothetical hyperplasia-microadenoma-
macroadenoma progression) and the rate of tumor
growth. In this, the potential role of other existing or
acquired genetic mutations as cofactors in permitting
AIP mutation-related tumor development will need to
be explored. Of great interest will be the further explo-
ration of Aip mutation-related tumorigenesis via the
knockout mouse models available, particularly because
these studies may relate to identifying the main caus-
ative pathway(s) among the legion of current possibil-
ities (dioxin, AHR, PDEs, etc.). Such advances may al-
low for specific therapies to be suggested that could
impact positively upon the relatively poor therapeutic
responses in these patients.
Search Strategy
Articles were selected from a PubMed, EMBASE, Web of
Science, Google Scholar, and GenBank search for key-
words including, e.g., AIP, XAP2, ARA9, FIPA, IFS, pi-
tuitary tumorigenesis, somatotropinoma, PAP, and pro-
tein interaction. Reference lists in selected articles were
also used to broaden the search, and abstract books of
recent national and international endocrinology con-
gresses were also consulted.
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